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ABSTRACT 
 
Modification of Bcl-x and Mcl-1 Pre-mRNA Splicing Using Splice-Switching 
Oligonucleotides 
(Under the direction of Ryszard Kole) 
 
Over 90% of multi-exon pre-mRNA transcripts undergo alternative splicing and up to 
one-half of disease-causing mutations affect splicing. Thus, alternative splicing has emerged 
as an important target for molecular therapies. Splice-switching oligonucleotides (SSOs) are 
chemically modified antisense oligonucleotides that hybridize to pre-mRNA sequences 
involved in splicing and block access to the transcript by splicing factors. As a result the 
splicing machinery is redirected to alternative splice sites thereby modifying the pattern of 
splicing and influencing protein expression. The efficacy of SSOs has been established in 
various animal disease models and clinical trials for Duchenne Muscular Dystrophy. 
However, the application of SSOs against cancer targets has been hindered by poor in vivo 
delivery of antisense therapeutics to tumor cells.   
 Bcl-x pre-mRNA is alternatively spliced to express anti-apoptotic Bcl-xL and pro-
apoptotic Bcl-xS. Bcl-xL expression is up-regulated in many cancers and confers 
chemoresistance, distinguishing it as an important target for cancer therapy. It was previously 
demonstrated that redirection of Bcl-x pre-mRNA splicing from Bcl-xL to -xS induced 
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apoptosis in breast and prostate cancer cells. In the research presented herein, the effect of 
SSO-induced Bcl-x splice-switching on metastatic melanoma was assessed in cell culture and 
B16F10 tumor xenografts. Delivery to tumor cells in vivo was achieved by encapsulating the 
SSO in targeted lipid nanoparticles. Administration of nanoparticle with Bcl-x SSO resulted 
in modification of Bcl-x pre-mRNA splicing in lung metastases and reduced tumor load, 
while nanoparticle alone or formulated with a control SSO had no effect. These findings 
demonstrate in vivo anti-tumor activity of SSOs that modulate Bcl-x pre-mRNA splicing. 
Like Bcl-x, Mcl-1 pre-mRNA is alternatively spliced to produce proteins with 
opposing functions. Splicing of all three Mcl-1 exons produces anti-apoptotic Mcl-1L, which 
is highly expressed in many malignancies and confers resistance to chemotherapeutic drugs. 
Skipping of exon 2 leads to expression of Mcl-1S, a potent pro-apoptotic protein expressed at 
low levels in most cells. I designed and screened SSOs targeted to the 5′ and 3′ splice sites of 
exon 2 in Mcl-1 pre-mRNA, which resulted in redirection of Mcl-1 pre-mRNA from Mcl-1L 
to -1S. Mcl-1 splice-switching resulted in PARP cleavage and cell death in HeLa cells, 
indicative of apoptosis. Mcl-1 splice-switching also sensitized cells staurosporine. These 
findings validate Mcl-1 as a target for SSOs to induce apoptosis and sensitize cancer cells to 
chemotherapy. 
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Pre-mRNA Splicing 
Pre-mRNA splicing is the co-transcriptional process of intron removal and exon 
joining in eukaryotes (Goldstrohm et al., 2001). In humans, the average human gene is 
28,000 nucleotides long and has 8.8 exons and 7.8 introns (Lander et al., 2001). The typical 
gene contains relatively short exons (e.g. 50–250 base pairs in length) separated by much 
larger introns (typically, hundreds of thousands of base pairs or more). Pre-mRNA splicing is 
mediated by the spliceosome, a dynamic complex of proteins and RNAs, which is assembled 
de novo on nascent transcripts. Sequence specificity and simultaneous plasticity of alternative 
splicing is achieved by tissue-dependent variability of spliceosome composition (Pollard et 
al., 2002; Pollard et al., 2000) and loose conservation of essential sequence elements in the 
pre-mRNA. These elements include splice sites, branch points, polypyrimidine tracts, and 
auxiliary exonic and intronic sequence elements known as splicing enhancers (ESEs and 
ISEs, respectively) and silencers (ESSs and ISSs, respectively) (Figure 1.1A). Splicing is 
thought to be controlled by competition among splice sites and splicing elements for splicing 
factors. 
Importantly, up to 50% of human genetic diseases arise from mutations that affect 
splicing and aberrations in splicing have been associated with cancer parthogenesis. 
(Cartegni et al., 2002; Faustino and Cooper, 2003; Pagani and Baralle, 2004; Pagenstecher et 
al., 2006). Thus, pharmacological agents that modify pre-mRNA splicing would potentially 
have therapeutic value (Bauman et al., 2009). 
Sequences Involved in Splicing 
 Sites in pre-mRNA that participate in every splicing reaction include the 5′ and 3′ 
ends of introns (referred to as 5′ and 3′ splice sites, respectively); the branch-point sequence 
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(BPS), an adenosine located upstream of the 3′ splice site; and the polypyrimidine tract, 
located between the branch point and the 3′ splice site (Figure 1.1 A). The first and last two 
nucleotides of an intron are conserved GU and AG, respectively. These absolutely conserved 
dinucleotides are flanked by loosely conserved splice site consensus sequences. The 5′ and 3′ 
splice sites, BPS and polypyrimidine tract are the sites of interaction with various 
components of the splicing machinery, and participate in the biochemical splicing reactions. 
 The core splicing elements are predicted to contain about half of the information 
required for splicing (Lim and Burge, 2001). The remaining information is derived largely 
from cis-regulatory sequence element (RSEs) that participate in splicing regulation. RSEs are 
classified as exonic and intronic splicing enhancers (ESEs and ISEs, respectively) and 
silencers (ESSs and ISSs, respectively) (Figure 1.1 A). SREs function by recruitment of 
sequence-specific RNA-binding factors that either activate or repress the use of adjacent 
splice sites. Interplay between these sequence elements is thought to control the outcome of 
each splicing event, providing the means for regulation of alternative splicing (Dominski and 
Kole, 1992). Many SREs have been identified through the study of disease-causing splicing 
mutations (Hua et al., 2007; Hua et al., 2008). Recently, high-throughput methods have 
accelerated the identification of SRE consensus sequences (Wang et al., 2004; Wang et al., 
2006). The eventual goal is to decipher the "cellular code" of splicing regulation to improve 
our capacity to predict alternative splicing outcomes (Wang and Burge, 2008). 
Chemical Reactions in Splicing 
 Splicing of pre-mRNA proceeds via two transesterification reactions (Figure 1.1 B). 
First, the 2′-hydroxel group of the branch point adenosine attacks the phosphate at the 5′ 
splice site. This leads to cleavage of the 5′ exon from the intron and the concerted ligation of 
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the intron 5′ end to the BPS 2′-hydroxyl. This step produces two reaction intermediates: a 
detached 5′ exon and an intron/3′-exon fragment in a lariat configuration containing a 
branched A nucleotide at the branch point. The second transesterification step is the attack on 
the phosphate at the 3′ end of the intron by the 3′-hydroxyl of the detached exon. This ligates 
the two exons and releases the intron in the form of a lariat (Black, 2003). 
The Spliceosome: A Dynamic Ribonucleoprotein Machine 
The spliceosome is a dynamic complex of small nuclear ribonucleoproteins (snRNPs) 
and accessory proteins, which is assembled de novo at every splicing event. The process of 
spliceosome assembly has been comprehensively reviewed and will be briefly summarized 
(Black, 2003; Staley and Guthrie, 1998; Wahl et al., 2009). The primary components of the 
spliceosome are the U1, U2, U4/U6 and U5 snRNPs.  Each snRNP consists of an snRNA 
(two in the case of U4/U5), and a variable number of complex-specific proteins. Spliceosome 
assembly begins with ATP-independent binding of the U1 snRNP through base-pairing 
interactions of the 5′ end of the U1 snRNA to the 5′ splice site. In higher eukaryotes, this 
interaction is stabilized by members of the serine-arginine-rich (SR) protein family. At the 
same time, SF1/BBP protein binds the branch-point adenosine (Baughan et al., 2006), and 
U2 auxiliary factor (U2AF), a dimer composed of 65 kDa and 35 kDa subunits, binds the 
polypyrimidine tract (Gaur et al., 1995). These two proteins bind cooperatively; SF1/BBP 
interacts with the 65 kDa subunit of U2AF (U2AF65) through its C-terminal RNA 
recognition motif (RRM).  In addition, the 35 kDa subunit of U2AF (U2AF35), binds the AG 
dinucleotide of the 3' splice site; this interaction is critical for introns with weak 
polypyrimidine tracts  (Wu et al., 1999). Together, these molecular interactions yield the E 
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(early) complex and play crucial roles in the initial recognition of the 5′ splice site and 3′ 
splice site (Black, 2003; Wahl et al., 2009). 
 After the formation of the E complex, the U2 snRNA engages in an ATP-dependent 
base-pairing interaction with the branch-point, leading to the formation of the A complex 
(pre-spliceosome). This base-pairing interaction is stabilized by heteromeric protein 
complexes of the U2 snRNP and by the arginine-serine-rich (RS) domain of the U2AF65 
protein (Valcarcel et al., 1996). Association of U2 leads to the displacement of SF1/BBP 
from the branch-point. The latter interaction is replaced by association of SF3b14a/p14 with 
the branch point adenosine. The SF3b155 protein now interacts with the C-terminal RNA 
recognition motif of U2AF65 (Wahl et al., 2009). 
Following A complex formation, the U4/U6 and U5 snRNPs are recruited as a 
preassembled U4/U6.U5 tri-snRNP, forming the B complex. This process requires SR 
proteins (ASF, SC35 and SRp55) and ATP hydrolysis (Roscigno and Garcia-Blanco, 1995). 
At this point, the required snRNPs are all present in the B complex, but it is still catalytically 
inactive and requires conformational and positional rearrangements in order to facilitate the 
first transesterification step of splicing. During spliceosome activation, U1 and U4 are 
destabilized or released, giving rise to the activated spliceosome (the B* complex).  The 
activated spliceosome then undergoes the first catalytic step of splicing, generating the C 
complex. Prior to the second catalytic step, additional rearrangements occur in the 
spliceosomal RNP network.  After the second catalytic step, the spliceosome dissociates, 
releasing the U2, U5 and U6 snRNPs to be recycled for additional rounds of splicing (Wahl 
et al., 2009).  
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The dynamic process of spliceosome assembly illustrates three recurring principles of 
the splice process. First, the core splicing elements are recognized multiple times by RNA or 
protein to ensure the precision of the splicing reaction. Second, functionally important 
interactions among components of the spliceosome are often weak but are enhanced by a 
combination of multiple interactions. Third, RNP rearrangements during spliceosome 
assembly generally involve the handing over of one of more binding partners to new 
interaction partners (Wahl et al., 2009).  
Splicing Factors 
Most ESEs recruit members of the SR protein family. SR proteins are characterized 
by their ability to interact simultaneously with RNA and other protein components via an N-
terminal RNA recognition motif (RRM) and through a C-terminal domain rich in arginine 
and serine residues, the RS domain (Caceres et al., 1997; Shepard and Hertel, 2009; Wang 
and Burge, 2008). For example, SR proteins facilitate binding of U1 snRNP to the 5′ splice 
site and U2AF65 to the polymyrimide tract (Staknis and Reed, 1994). SR proteins are also 
required from the pre-spliceosome (A complex) to spliceosome (B complex) transition, as 
their depletion inhibits spliceosome assembly (Roscigno and Garcia-Blanco, 1995). 
ESSs are often bound by splicing repressors of the hnRNP class, a diverse group of 
proteins containing one or more RNA-binding domains and sometimes splicing inhibitory 
domains, such as glycine-rich motifs (Han et al., 2010). The hnRNP proteins vary in their 
mechanism of action: they can repress splicing by directly antagonizing the recognition of 
splice sites, or can interfere with the binding of proteins bound to enhancers (Martinez-
Contreras et al., 2007). Polypyrimidine tract biding protein (PTB, also hnRNP I) blocks 
interactions between U1 and U2 snRNPs (Sharma et al., 2005), while hnRNP A1 inhibits 
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splicing by binding on either side and looping out exons, or by directly displacing snRNP 
binding (Nasim et al., 2002; Zhu et al., 2001).  
There are fewer examples of well-characterized intronic rather than exonic RSEs. 
One example is G triplet or G run (Gn; n ≥ 3), which are often present in clusters and can 
enhance recognition of adjacent splice sites (McCullough and Berget, 2000). Characterized 
ISSs include binding sites for the aforementioned PTB and hnRNP AI splicing repressors 
(Matlin et al., 2005), CA-rich sequences bound by hnRNP L (Hui et al., 2005), and specific 
octamers flanking exon IIIb of the FGFR2 gene (Wagner et al., 2005). Interestingly, intronic 
RSEs are thought to be of particular importance in regulating alternative splicing because the 
intronic regions surrounding alternatively spliced exons are far more conserved in mammals 
than those surrounding constitutive exons (Sorek and Ast, 2003). This increased conservation 
has been used to predict unannotated alternative exons (Sorek et al., 2004) and to predict 
intronic SREs (Yeo et al., 2007).  
Alternative Splicing 
Through alternative splicing, a single pre-mRNA transcript can give rise to multiple 
mature mRNA splice variants, which are then translated into variable protein isoforms. This 
is accomplished through various means, including exon exclusion, intron retention, exon 
shuffling, alternative 5′ and 3′ splice sites, alternative promoter usage and alternative 
polyadenylation site selection (Figure 1.2). According to deep sequencing analyses, over 
90% of multi-exon genes undergo alternative splicing, approximately 86% with a minor 
isoform frequency of 15% or more (Wang et al., 2008).  Most alternative splicing events 
affect the coding sequence, with half of these altering the reading frame and one-third 
apparently leading to nonsense-mediate decay of the RNA product (Thanaraj et al., 2003). 
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Regulation of alternative splicing is thought to involve the participation of core 
splicing elements and RSEs, with the precise combinations and relative ratios of factors 
dictating regulatory decisions. Tissue-specific splicing decisions might be determined by 
cellular codes comprised of particular combinations of splicing regulators specific to each 
cell type. As a result, many alternative splicing events involve a complex interplay between 
positive and negative regulators that function through cognate enhancers and silencers 
(Dominski and Kole, 1992; Matlin et al., 2005). The dynamic nature and the gene- and 
tissue-dependent variability of the splicing machinery and its interaction with pre-mRNA 
suggest a richness of potential targets for drugs that interfere with or redirect alternative 
splicing pathways for therapeutic purposes (Kole et al., 2004). 
Splice-switching oligonucleotides 
Antisense oligonucleotides (ASOs) can be broadly defined as oligonucleotides 8 to50 
nucleotides in length that, entirely or in part, bind RNA through Watson-Crick base pairing 
and upon binding to RNA, modulate the function of the targeted RNA (Bennett and Swayze, 
2010). These compounds act by various mechanisms either to promote the degradation of the 
RNA or to modify its function in some way without promoting degradation. Perhaps the best 
understood mechanism resulting in target RNA degradation is cleavage by ribonuclease H 
(RNase H), which cleaves DNA:RNA duplexes (Lima et al., 2008). Another widely studied 
mechanism of RNA degradation is RNA interference (RNAi), which involves loading of 
double-stranded mRNA substrates into a protein complex called RISC, followed by cleavage 
of the target mRNA by the enzymatic Argonaute protein (Sigova and Zamore, 2008). 
Antisense mechanisms of regulation that do not involve cleavage of the target RNA include 
9 
 
translation arrest (Deas et al., 2005), inhibition of translation initiation (Baker et al., 1997) 
and modification of splicing (Dominski and Kole, 1993).  
Modification of pre-mRNA splicing was first demonstrated in cell-free extracts from 
cells expressing aberrantly-sliced β-globin. Dominski and Kole (1993) discovered that 
blocking an active splice site with an antisense oligonucleotide does not lead to the complete 
shut down of splicing in that transcript, but simply forces the spliceosome to select an 
alternative splicing pathway. In this study, human β-globin pre-mRNAs with splicing 
mutations were targeted with RNase H non-competent 2′-O-methyl antisense 
oligonucleotides in order to restore correct splicing. Antisense oligonucleotides targeted 
against aberrant 5′ and cryptic 3′ splice sites activated by IVS2-705 and IVS2-654 mutations 
in intron 2 significantly inhibited the aberrant splicing and restored the correct splicing 
pathway. This study demonstrated that oligonucleotides could compete with splicing factors 
for access to pre-mRNA sequence elements and modify the pattern of splicing. A subsequent 
study in mammalian cells expressing the IVS2-654 human β-globin gene confirmed that the 
oligonucleotide could enter the cell, reach the nucleus and modify the pattern of splicing in a 
sequence-specific manner in live cells (Sierakowska et al., 1996). Antisense oligonucleotides 
that modify splicing comprise a distinct class of antisense compounds and have been termed 
splice-switching oligonucleotides (SSOs). 
Oligonucleotide Chemical Modifications  
The SSO mechanism of action requires that it form very stable duplexes with its pre-
mRNA target to enable successful competition with natural splicing factors for specific 
binding sequences. This must be achieved without activating RNase H. These requirements 
are met by incorporating various chemical modifications of the oligonucleotide backbone and 
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ribose ring that improve binding affinity and do not support RNase H cleavage (Sazani et al., 
2001). Down-regulating ASOs are limited in the degree to which they can be modified 
because they require at least five contiguous deoxyribonucleotides to support RNase H 
cleavage (Monia et al., 1993). Chimeric ASOs, or "gapmers," consisting of a 
deoxyribonucleotide region flanked by modified nucleotides are RNase H-active and derive a 
partial benefit due to the modified flanks. Because some modified nucleotides interfere with 
loading into the RISC complex, siRNA is even more limited in the degree to which they can 
be modified. 
In addition to RNase H non-competence, the SSO must be resistant to enzymatic 
degradation in the cellular environment and should demonstrate preferential tissue 
distribution and pharmacodynamics in vivo. The chemical modifications that best meet all the 
desired SSO criteria are discussed in the following sections. 
Phosphorothioate Modification 
In biological fluids, unmodified deoxyribonucleotides are highly susceptible to 
degradation by ubiquitous nucleases and  in vivo they exhibit circulating half-lives of 1–2 
minutes (Levin  et al., 2008). Modifying the phosphodiester (PDE) backbone of DNA ASOs 
renders them resistant to cleavage by nucleases. The widely used phosphorothioate (PS) 
modification substitutes a sulfur for a non-bridging oxygen atom in the PDE linkages (Figure 
1.3 A); this modification improves nuclease stability such that the plasma half-life of these 
ASOs is increased to 30–60 minutes. The PS modification does not impart RNase H non-
competence, however, and must be used in conjunction with other modifications that do not 
support RNase H to be applied for splice-switching. 
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 In addition to increased nuclease resistance, the PS modification confers enhanced 
protein binding (Brown et al., 1994). The reason PS ASOs bind more promiscuously to 
cellular proteins than PDE ASOs has not been fully elucidated, but may be due to increased 
lipophilicity and metal ion complexation (Levin  et al., 2008). Interactions of the sulfurs in 
the PS ASOs with metal ions associated with specific proteins have been proposed for the 
affinity of PS ASOs for proteins (Eckstein, 2000). Binding of PS ASOs to several abundant 
serum proteins including albumin, fibrinogen, and γ-globulin, has been reported (Yu et al., 
2000). The increased binding of PS ASOs to serum proteins may contribute to increased 
cellular toxicity of these drugs. In primates, a PS DNA ASO activated the complement 
cascade following rapid infusion and in some cases, led to cardiovascular collapse and death; 
however, lower doses used in human clinical trials have been well-tolerated (Nemunaitis et 
al., 1999). In addition, increased serum protein binding protects PS ASOs from renal 
filtration and contributes to the increased serum half-life (Levin, 1999). The PS modification 
imparts slightly reduced binding affinity towards complementary RNA compared to 
unmodified ASOs.  Thus, the enhanced nuclease stability of PS ASOs comes at the expense 
of target binding affinity and increased toxicity. These drawbacks can be compensated for by 
incorporation of other modifications. Unless specifically stated otherwise, all 2OMe, MOE 
and LNA SSOs described in this manuscript contained PS internucleotide linkages. 
2′-Modifications of Ribose 
Substitutions at the 2′ position of ribose impart RNase H non-competence to fully-
modified SSOs.  The two most widely studied in this group are the 2′-O-methyl (2OMe) and 
2′-O-methoxyethyl (MOE) modifications (Figure 1.3 B, C). Oligonucleotides that employ 
these ribose modifications, coupled with PS internucleotide linkages, exhibit diminished 
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toxicity and enhanced target sequence binding compared to PS DNAs. The first report 
showing in vivo activity of SSOs utilized both of these chemistries (Sazani et al., 2002). 
Since then, numerous groups have used 2OMe (Lu et al., 2003; Lu et al., 2005; Mann et al., 
2001) and MOE (Hua et al., 2008; Vickers et al., 2006) SSOs to modulate splicing in vivo. 
Among the chemistries employed for oligonucleotide therapeutics, the MOE modification 
has been studied in the most detail, with 15 MOE ASOs currently in clinical trials 
(www.isispharm.com/pipeline). 
Locked nucleic acids (LNA) consist of a ribonucleotide containing a methylene 
bridge that connects the 2′-oxygen of the ribose with the 4′-carbon (Figure 1.3 D). 
Introduction of LNAs into a DNA ASO induces a conformational change of the DNA-RNA 
duplex towards the A-type helix, and therefore prevents the RNase H cleavage of the target 
RNA. Chimeric DNA-LNA ASOs exhibit enhanced stability against nucleolytic degradation 
and remarkably high target affinity (Wahlestedt et al., 2000). The enhanced binding affinity 
enables the use of lower SSO concentrations in vitro and in vivo (Roberts et al., 2006). A 
study of SSOs consisting of various proportions of DNA, 2OMe and LNA monomers 
demonstrated that the introduction of LNA monomers enhanced antisense activity 
(Guterstam et al., 2008). However, this study also found that, due to their high target affinity, 
LNA monomers also confer low mismatch discrimination to the SSO, which could result in 
increased off-target effects and related toxicity. This potential drawback could be addressed 
by using shorter oligonucleotides or by tuning of the proportion of LNA monomers in an 
SSO to optimize the trade-off between splice-switching efficiency and risk for off-target 
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Backbone Modifications 
Phosphoroamidate morpholinos (PMOs) are nonionic DNA analogs in which the 
ribose is replaced by a morpholino moiety and phosphoroamidate intersubunit linkages are 
used instead of PDE bonds (Figure 1.3 E). They have high nuclease resistance, high duplex 
stability and do not activate RNase H (Morcos, 2007). Because they are uncharged, PMOs 
are unlikely to form unwanted interactions with nucleic acid-binding proteins; however, their 
cellular uptake is limited (Sazani et al., 2002). In cynomolgus monkeys, no toxicity was 
detected at the maximum feasible dose (320 mg/kg) (Sazani et al., 2010) and no adverse 
effects were reported following intramusculuar injection in human clinical trials (Kinali et 
al., 2009). 
Peptide nucleic acids (PNA) consist of a DNA analog wherein the deoxyribose 
phosphate backbone is replaced by polyamide linkages (Figure 1.3 F). PNAs exhibit high 
target affinity, are nuclease and peptidase-resistant and do not activate RNase H. However, 
they are electrostatically neutral and their ability to cross cell membranes is limited. This 
limitation can be overcome by the addition of positively charged amino acids at the 5′ or 3′ 
end (Abes et al., 2006; Sazani et al., 2002; Sazani et al., 2001). 
Delivery of SSOs  
In order for the SSO to affect splicing, it must reach its pharmacological site of action 
in the nucleus. In cell culture, antisense activity of free SSOs is generally modest and as a 
result commercially available transfection reagents, such as Lipofectamine2000 (Wan et al., 
2008) and DMRIE-C (Mercatante et al., 2001), are commonly used to improve delivery. 
Without the aid of delivery agents, uncharged or positively charged SSOs (e.g. morpholino, 
PNA) reached the nucleus more efficiently than negatively-charged compounds (e.g. 2OMe, 
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MOE) (Sazani et al., 2001). The poor efficacy of the 2OMe and MOE SSOs appeared to be 
due not to poor cellular uptake but to sequestration of these compounds in the cytoplasm or 
cytoplasmic vesicles (e.g. endosomes) following uptake. Incorporation of G-clamp and 
phenoxazine analogs of cytidine into MOE SSOs resulted in a modest increase in antisense 
activity compared to unmodified MOE SSOs (Sazani et al., 2003). The addition of four 
positively-charged lysines increased the antisense activity of a PNA SSO (Sazani et al., 
2001). Treatment with endosome-disrupting agents resulted in a dramatic increase in the 
antisense activity of a PNA SSO conjugated with eight lysines without improving the activity 
of the free PNA SSO, suggesting that the former efficiently entered the cell but was 
sequestered in endosomal vesicles (Abes et al., 2006).  
In vivo delivery of SSOs presents additional challenges that are not encountered in 
cell culture. The biological barriers to effective SSO delivery and how they may be overcome 
are discussed in the following sections. 
Biological Barriers Encountered by SSOs In Vivo 
 Several major biological barriers must be overcome in order for SSOs to be useful as 
therapeutic agents. The first barrier encountered by the SSO in vivo is comprised of 
ubiquitous nucleases in plasma and tissues. The major activity in plasma is a 3′ exonuclease, 
however cleavage of the internucleotide bonds also takes place (Juliano et al., 2009a). In 
general, oligonucleotides accumulate in most tissues, particularly the liver and kidney, but 
not the central nervous system. The precise pharmacokinetics and functional distribution of 
an SSO depend on its chemical composition (Sazani et al., 2002). However, the 
biodistribution of an oligonucleotide does not predict the tissues in which it will be 
functionally active (Roberts et al., 2006).  
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Another consideration is clearance by macrophages of the reticuloendothelial system 
(RES). The RES is composed of phagocytic cells, including circulating monocytes and 
macrophages, whose physiological function is to clear the body of foreign pathogens, remove 
cellular debris that is generated during tissue remodeling, and clear cells that have undergone 
apoptosis (Mosser and Edwards, 2008). Tissue macrophages are most abundant in the liver 
(Kupffer cells) and spleen, tissues that also receive high blood flow and exhibit fenestrated 
vasculature (Underhill and Ozinsky, 2002). Thus is it not surprising that these organs 
accumulate high concentrations of oligonucleotide (Geary et al., 2008; Roberts et al., 2006).  
In order to reach a particular tissue, the oligonucleotide must cross the endothelial 
cells that line the vasculature. These cells adhere tightly to the underlying extracellular 
matrix via integrins and form junctions with one another via cell-cell adhesion molecules. A 
model has been proposed that describes normal endothelium as having abundant 45 Å 
diameter pores as well as relatively scarce large pores of 250 Å (Rippe et al., 2002). Based on 
the molecular weights of oligonucleotides, they should be able to extravasate from 
circulation via these small pores. There is controversy regarding the role of the large pore 
system and it is not known whether its contributes to extravasation of oligonucleotides 
(Juliano et al., 2009a).  
In contrast to normal endothelium, tumor vasculature presents abnormalities that 
provide opportunities and obstacles to oligonucleotide delivery. The transvascular 
permeability of tumors is generally higher than that of normal tissue, likely due to an 
increased number and size of the “large pore” component (Jain, 1999). Tumor vasculature 
tends to be more highly fenestrated than normal tissue and exhibit poor lymphatic drainage. 
These characteristics might enable macromolceules to more easily cross into and persist in 
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tumor tissue, the so-called enhanced permeability and retention (EPR) effect (Brannon-
Peppas and Blanchette, 2004). However, tumors also frequently exhibit high interstitial fluid 
pressure, which works against the uptake of macromolecules (Juliano et al., 2009a). 
Oligonucleotides enter cells by some form of endocytosis, which requires 
coordination of cellular uptake, vesicular trafficking and endosomal release. Injection of 
mice with increasing doses of a nonsense ASO in combination with a constant concentration 
of a therapeutic MOE SSO resulted in an increase in antisense activity of the latter, 
suggesting the presence of a nonproductive bulk uptake pathway (Geary et al., 2009). The 
SSO site of action is the nucleus (Sazani et al., 2003), thus their pharmacological effect 
depends not only on total cell update but also on intracellular trafficking of the SSO, which 
to date is poorly understood (Alam et al., 2008).  
Systemic Administration of Free SSOs 
The simplest approach to in vivo delivery of SSO is systemic administration of free 
oligonucleotide. This was first documented by Sazani and colleagues, who engineered an 
animal model for the study of SSO activity in vivo. The assay is based on a transgenic mouse 
that ubiquitously expresses the coding sequence for enhanced green fluorescence protein 
(EGFP) with an aberrantly spliced intron of human β-globin intron 2 (IVS-654; see earlier 
section on origins of SSOs for more detail), such that basal expression of EGFP protein is 
essentially zero (Sazani et al., 2002). Delivery of SSO to the nuclei of cells corrects the 
aberrant splicing and leads to generation of mRNA containing the correct EGFP reading 
frame and renders the cells fluorescent, providing a positive readout of nuclear 
oligonucleotide activity.  
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With the advent of the so-called EGFP-654 mouse, the in vivo efficacies of 
systemically delivered SSOs containing various chemical modifications could be compared 
in a controlled system. In contrast to earlier observations in cell culture (Sazani et al., 2001), 
MOE SSOs demonstrated strong antisense activity in a number of tissues, including liver, 
small intestine, lung and heart (Sazani et al., 2002). Neutral morpholino and PNA SSOs 
exhibited only modest activity; however addition of four lysines significantly enhanced their 
activity (PNA-4K). LNA SSOs were found to be active almost exclusively in the liver and, to 
a lesser extent, the small intestine and colon (Roberts et al., 2006). The LNA SSO was 
considerably more potent than the 2OMe SSO in these tissues. In the liver, the LNA SSO 
exhibited an EC50 that was approximately 17-fold higher than that of the 2OMe SSO. This 
was likely due to higher binding affinity conferred by the LNA bases. Little activity was seen 
in the kidney, the tissue with by far the greatest LNA SSO accumulation, indicating that the 
sites of SSO biodistribution do not necessarily predict the sites of its pharmacological 
activity (Roberts et al., 2006). Taken together, these results indicated that systemically 
delivered free SSOs exhibited distinct functional activity profiles depending on their 
chemical composition in the EGFP-654 model system.  
 Administration of free SSOs did not result in detectable antisense activity in tumor 
cells in various tumor xenograft models. Over the course of several related studies, over 254 
mice were implanted with subcutaneous tumor xenografts (508 total tumors) using different 
cell lines. Despite using more aggressive dosing regimens than were used in the studies 
described above (25 mg/kg daily injections over two weeks vs. 25–50 mg/kg daily injections 
over four days), the investigators failed to detect antisense activity of MOE SSOs (Adams 
and Kole, unpublished data). The investigators also failed to detect SSO activity in orthotopic 
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liver xenografts (42 mice implanted). In summary, antisense activity could not be confirmed 
in tumor xenografts following systemic administration of free SSO. 
Peptide Conjugates to Improve Delivery 
Two main strategies have emerged for improving delivery of oligonucleotide 
therapeutics: cell targeting or cell penetrating peptide (CPP) conjugates and nanoparticles 
(see next section). Because the SSO mechanism of action enables up-regulation of reporter 
gene expression, SSOs constitute ideal tools for investigating novel delivery agents for 
oligonucleotides in general (Kang et al., 1998). As a result, to date many peptide conjugates 
have been investigated in cell culture (Alam et al., 2008; Kang et al., 2008; Marlin et al., 
2010). However, fewer peptide conjugates have been validated in vivo. Jearawiriyapaisarn et 
al. screened in the EGFP-654 mouse a panel of putative cell penetrating peptides containing 
different combinations of arginine, 6-aminohexanoic acid, and β-alanine conjugated to PMO 
SSOs (Jearawiriyapaisarn et al., 2008). Many of the peptide-conjugated PMOs (PPMOs) 
exhibited potent antisense activity in numerous tissues. In particular, one PMO-peptide 
conjugate, PPMO-B, induced significant antisense activity in body-wide skeletal muscle, 
diaphragm and cardiac muscle, distinguishing the PPMO-B peptide as potentially useful for 
muscle-related targets. Others have reported similar results with arginine-rich CPPs 
(McClorey et al., 2006; Moulton et al., 2007; Wu et al., 2008; Yin et al., 2008a; Yin et al., 
2008b), several of which are currently being investigated in the clinic for the modification of 
splicing in the Duchenne Muscular Dystrophy (see later section on DMD).  
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Lipid Nanoparticles for Oligonucleotide Delivery 
Because they cannot tolerate many chemical modifications, efforts to improve siRNA 
delivery have involved nanoparticle encapsulation to protect them from premature 
degradation by nucleases. As a result, there is a large body of research on nanoparticle 
delivery of siRNAs in vivo (Akhtar and Benter, 2007).  In contrast, to date only one study has 
utilized a non-peptide conjugate delivery aid for SSOs in vivo: a commercially available 
triblock copolymer, Pluronic F127, delivered 2OMe SSOs to body-wide skeletal muscle 
following i.v. injection, resulting in a low but detectable level of antisense activity (Lu et al., 
2005).  It seems likely that nanoparticle formulations that prove successful in delivery siRNA 
may be applied for the delivery of SSOs.  
Among the formulations that have proven effective in the delivery of siRNA in vivo 
are lipid-based nanoparticles. Cationic lipids can condense nucleic acids into a cationic 
particle known as a lipoplex. Lipoplex formations protect the nucleic acid cargo from 
enzymatic degradation and can deliver it into cells by interacting with the negatively charged 
cell membrane. However, lipoplexes suffer high toxicity—likely related to charge—and have 
performed poorly in clinical trials (Edelstein et al., 2004; Lv et al., 2006). To overcome 
toxicity issues and to extend circulation time, the nucleic acid cargo can be encapsulated into 
a polyethylene glycol (PEG)-shielded cationic liposomal bilayer using scalable formulation 
methods (Choi et al., 2003; Harvie et al., 2000; Jeffs et al., 2005; Li et al., 2005; Wheeler et 
al., 1999; Zhang et al., 1999). These PEG-shielded cationic particle differ from lipoplexes by 
having a bilayer shell around the nucleic acid cargo, a smaller particle diameter (<100 nm) 
and better stability in vivo.   
20 
 
Li and Huang recently developed a multi-component lipid nanoparticle that 
effectively delivered siRNA and RNase H-active ASOs to tumor cells in culture, and siRNA 
to tumor xenografts in vivo (Li and Huang, 2006a). The formulation was prepared by 
encapsulating the siRNA using calf thymus DNA as a carrier DNA, providing protection 
against nucleases (See Figure 2.4 for schematic representation). The complex was condensed 
using protamine and then coated with cationic liposomes consisting of cholesterol and a 
cationic lipid. PEG lipids were inserted into the liposomal bilayer to shield the positive 
charge, reduce aggregation and increase circulation time in the blood. PEGylated 
nanoparticles have been reported to accumulate in highly vascularized tissues (the 
aforementioned EPR effect) (Brannon-Peppas and Blanchette, 2004). To increase cellular 
uptake, ligands may be tethered to the distal end of PEG to trigger receptor-mediated 
endocytosis. Li and Huang used anisamide, a ligand that binds the sigma receptor, which is 
aberrantly expressed at the tumor cell surface in various cancers (Banerjee et al., 2004; Bem 
et al., 1991).  Based on its composition, Li and Huang referred to this lipid-based 
nanoparticle as a liposome-polycation-DNA complex, or LPD. 
In its first application, the LPD NP delivered either siRNA or ASO targeted to 
survivin into sigma receptor-expressing H1299 lung cancer cells, resulting in reduced 
survivin mRNA and protein expression, and increased apoptosis and chemosensitization (Li 
and Huang, 2006b). These effects were significantly diminished in the presence of 
haloperidol, a high affinity sigma receptor ligand, suggesting that the conjugation of 
anisamide improved cell uptake. Li and Huang used this study to optimize the LPD 
formulation by fine-tuning the ratio of siRNA/ASO:protamine:liposome.  
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Next, Li and Huang used the LPD NP to deliver siRNA to tumor cells in vivo. LPD 
NP carrying siRNA targeted to EGFR was administered by three consecutive daily injections 
of 1.2 mg siRNA/kg to mice bearing H460 lung cancer subcutaneous xenografts (Li et al., 
2008a). This treatment resulted in significant knockdown of EGFR expression, a modest 
induction of apoptosis (~15% vs. ~3 in PBS-treated animals), and reduced tumor growth. 
These effects were not seen in animals treated with LPD NP carrying a scrambled control 
siRNA. Non-targeted LPD NP carrying EGFP siRNA showed an intermediate level of tumor 
cell uptake that was greater than free siRNA but less than targeted LPD NP; however, it 
failed to silence EGFR or inhibit tumor growth. This suggested that improved uptake 
facilitated by the anisamide ligand was necessary for anti-cancer effects. 
 Li and colleagues next employed a common tumor model wherein sigma receptor-
expressing B16F10 murine melanoma cells are injected into the tail vein and rapidly colonize 
the lungs. Using cells stably expressing luciferease, they demonstrated that LPD NP carrying 
luicferase siRNA could achieve 70–80% knock-down expression of reporter gene expression 
following a single 0.15 mg siRNA/kg i.v. injection (Li et al., 2008b). No cytokine induction 
was detected and uptake was relatively specific for tumor cells. LPD NP carrying three 
siRNAs targeted to MDM2, c-myc, and VEGF dramatically reduced tumor burden (by 70–
80%) following two consecutive daily injections of 0.45 mg total siRNA/kg (0.15 mg each 
siRNA/kg) (Li et al., 2008c). This regimen improved survival time by 30%. Once again, 
target gene silencing and anti-tumor effects were absent in non-targeted LPD NP and LPD 
NP carrying scrambled siRNA. Higher doses of LPD NP (≥1.2 mg siRNA/kg) resulted in 
induction of IL-12 and IL-6 cytokines. 
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The impressive results using the LPD NP carrying siRNA prompted us to ask whether 
it could also be used to deliver SSO to the nucleus in tumor xenografts. This hypothesis was 
tested in Specific Aim 1. 
Examples of SSO targets 
SSOs may be applied in several ways: (i) to restore correct splicing of an aberrantly 
spliced transcript, (ii) to shift existing alternative splicing patterns from one splice variant to 
another, and (iii) to induce a novel splice variant that is not normally expressed (Figure 1.4) 
(Sazani P, 2007). The following section provides examples of how these splice-switching 
strategies have been applied against therapeutically relevant targets. This list is not 
comprehensive, but includes targets that have been thoroughly characterized in vitro and in 
vivo: β-globin, SMN2, TNFR2, MyD88, HER2 and ATM (Bcl-x is discussed in a later 
section). Special attention is devoted to SSOs applied to restore dystrophin expression in 
Duchenne Muscular Dystrophy because this is the first application to progress to clinical 
trials.  
β-thalassemia 
The blood disease β-thalassemia is caused by mutations in the β-globin a gene, many 
of which disrupt pre-mRNA splicing of introns one and two. Among the common β-globin 
mutations that disrupt splicing are IVS-654 and IVS-705, which create aberrant 5′ splice sites 
at positions 654 and 705, respectively, and activate the same cryptic 3′ splice site in intron 2.  
These mutations cause a portion of the intron to be retained in the spliced transcript, which 
introduces a shift in the reading frame that produces a premature stop codon. Dominksi and 
Kole showed that oligonucleotides targeted to these mutations restored normal splicing of β-
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globin mRNA (Dominski and Kole, 1993). This study demonstrated that oligonucleotides 
could compete with splicing factors for access to pre-mRNA sequence elements and modify 
the pattern of splicing. A subsequent study in mammalian cells expressing the IVS2-654 
human beta-globin gene confirmed that the oligonucleotide could enter the cell, reach the 
nucleus and modify the pattern of splicing in a sequence-specific manner in live cells 
(Sierakowska et al., 1996).  
In erythroid progenitor cells isolated from peripheral blood of patients carrying IVS2-
654 or -745 mutations, a single treatment with PMOs targeted to aberrant 5′ splice sites by 
syringe loading resulted in correction of β-globin pre-mRNA splicing and production of 
hemoglobin A (HbA) (Lacerra et al., 2000). Moreover, the PMOs were freely taken up by 
erythroid progenitor cells isolated from bone marrow of β-thalassemic mice carrying the 
human βIVS2-654 mutation (Lewis et al., 1998) and from peripheral blood of patients 
carrying IVS2-654 mutation, leading to effective splicing correction (Suwanmanee et al., 
2002b). Free uptake of PMOs was also shown to be effective in splicing correction and HbA 
restoration in progenitor cells isolated from patients carrying a hemoglobin E mutation that 
activates a cryptic 5′ splice site in exon 1 (Suwanmanee et al., 2002a). These results 
suggested that PMO would be applicable in vivo, in mouse models of β-thalassemia. 
Using an arginine-rich peptide, PMO SSO was delivered to a mouse model of IVS2-
654 thalassemia. The SSO restored normal splicing resulting in significant expression of 
hemoglobin in peripheral blood, improving the number and quality of erythroid cells (Svasti 
et al., 2009). 
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SMN2 
Spinal muscular atrophy (SMA) is characterized by the progressive degeneration of 
the motor neurons leading to a muscle wasting caused by homozygous mutations or deletions 
in the survival of motor neuron 1 gene (SMN1). SMN1 is ubiquitously expressed and encodes 
SMN protein, which is necessary for assembly of snRNPs involved in splicing, an essential 
process for cell survival (Wan et al., 2005). In humans there is a second, SMN gene copy, 
SMN2, which differs from SMN1 in the C-to-T transition at position 6 of SMN2 exon 7. It 
has been proposed that this transition disrupts an ESE sequence (Cartegni and Krainer, 
2002), creates an ESS sequence (Kashima and Manley, 2003), or strengthens an inhibitory 
RNA stem loop at the 5′ end of exon 7 (Singh et al., 2004), leading to exon 7 exclusion in 
most of SMN2 transcripts that yields an unstable truncated SMN protein. SMN2 is a 
modifying gene in SMA patients, as the number of copies of SMN2 is inversely correlated to 
the severity of SMA (Mailman et al., 2002). Therefore, a strategy to include exon 7 and up-
regulate expression of full-length, fully functional SMN protein from the intact copies of 
SMN2 present in SMA patients can offer a therapeutic approach for SMA. Indeed, masking 
the 3′ splice site of SMN2 intron 7 using a 2OMe SSO impaired splice site recognition and 
forced the splicing machinery to re-couple the 5′ and 3′ splice sites in intron 6, leading to 
increased inclusion of exon 7 in cell culture (Lim and Hertel, 2001).  
Targeting exon 7 by SSOs either linked to serine/arginine-rich splicing factors or 
including a “tail” that serves as a splicing factor binding site, called exon-specific splicing 
enhancement by small chimeric effectors (ESSENCE) (Cartegni and Krainer, 2003) and 
targeted oligonucleotide enhancer of splicing (TOES) (Skordis et al., 2003), respectively, 
have also been shown to promote exon 7 inclusion.  A synthetic ESSENCE molecule 
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containing a PNA SSO targeted to exon 7 coupled to ten arginine-serine (RS) repeats 
significantly induced exon 7 inclusion in a cell-free splicing system. Although the PNA SSO 
lacking the RS repeats was active, efficacy was much lower than the ESSENCE molecule. 
The TOES was designed to have two components; the first was complementary to exon 7 and 
second was a non-complementary sequence which was designed to mimic an ESE to recruit 
trans-splicing factors. This bifunctional SSO increased SMN2 exon 7 inclusion in vitro and 
in SMA patient fibroblasts, which led to partial restoration of gem number, an indicator of 
SMN protein increase, suggesting that SSO bound to exon 7 in the transcript did not interfere 
with translation.  
In a subsequent study, SMN2 exon 7 was saturated with overlapping MOE SSOs 
(Hua et al., 2007). The cell culture experiments revealed that the most effective SSOs, which 
promoted exon 7 inclusion and increased full-length SMN protein in SMA patient 
fibroblasts, were targeted to two putative exon splicing silencers (ESS) close to the 3′ and 5′ 
splice sites, respectively. These results imply that blocking of the ESS is sufficient to induce 
exon inclusion and that ESSENCE or TOES modifications, although most likely helpful, are 
not essential.   
SSO targeted to a putative ISS in intron 6 identified also prompted an increase in 
exon 7 inclusion in the context of a SMN2 minigene (Miyajima et al., 2002). The ISS, called 
ISS-N1, was subsequently identified immediately downstream of the 5′ splice site of intron 7 
(Singh et al., 2006). An extensive SSO screen of sequences downstream of the 5′ splice site 
in intron 7 identified the same ISS (Hua et al., 2008). Recently, MOE-PS SSO targeted to 
ISS-N1 was administered to human SMN2 (hSMN2) transgenic mice by biweekly i.v. 
injections at 25 mg/kg. Significant exon 7 inclusion was observed in the liver and kidney, but 
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not in the spinal cord of treated mice (Hua et al., 2008). In order to achieve the therapeutic 
effect of this strategy in SMA, the SSO would need to cross the blood-brain barrier or be 
delivered directly to the central nervous system. 
TNFR 
The cytokine tumor-necrosis factor-α (TNF-α) plays an important role in 
inflammatory diseases such as rheumatoid arthritis and hepatitis. TNF-α signaling is 
mediated by two membrane-bound receptors, TNFR1 and TNFR2, which trimerize upon 
ligand binding, leading to downstream activation of the transcription factor NF-κB. 
Approved anti-TNF-α macromolecular drugs etanercept (a dimerized TNFR2 receptor:Fc 
fusion protein), and infliximab and adalimumab (anti-TNF-α monoclonal antibodies), bind 
TNF-α in circulation and inhibit its inflammatory effects. 
 Graziewicz and colleagues hypothesized that exclusion of the transmembrane 
domain-encoding exon 7 would create a novel soluble protein, ∆7TNFR2, capable of 
antagonizing TNF-α signaling. They screened 16-mer SSOs consisting of alternating LNA-
DNA nucleotides with PS linkages in L929 mouse cells and identified SSO3274, which 
efficiently blocked the 5′ splice site of exon 7 in TNFR2 pre-mRNA, inducing exon skipping 
in a sequence-specific and dose-dependent manner. SSO3274-induced exon skipping resulted 
in the expression of soluble ∆7TNFR2 protein, which was detected in the culture medium 
and which exhibited anti-TNF activity (Graziewicz et al., 2008).  
 LNA-containing SSOs are remarkably potent in the liver, where TNFR2 is highly 
expressed (Roberts et al., 2006). This led to an approach to utilize the liver as a “protein 
factory,” producing soluble ∆7TNFR2 for release into circulation to antagonize TNF-α. As 
expected, SSO3274 induced sequence-specific, dose-dependent, persistent splice-switching 
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in the mouse liver after five daily i.p. injectons at 25 mg/kg/day. ∆7TNFR2 protein was 
detected in the serum of SSO3274-treated animals at 8,000–10,000 pg/ml, exhibited potent 
anti-TNF activity and was detectable in circulation up to 35 days after the last injection. 
Serum containing ∆7TNFR2 from SSO3274-treated mice (25 mg/kg/day i.p. once daily for 
10 days) was 10-fold more potent at than that from mice treated with etanercept (50 µg i.p. 
once daily for 5 days). Evidently etanercept was subject to in vivo degradation that reduced 
its activity, while SSO3274 continually induced additional ∆7TNFR2 protein, replenishing 
degraded or inactivated protein in circulation. Importantly, no SSO-induced toxicity was 
reported. Because SSOs induce the expression of endogenous protein the likelihood of 
immune toxicity is very low. The ability of SSOs to produce therapeutic splice variants, such 
as ∆7TNFR2, for extended time periods and with a low likelihood of immune toxicity is a 
distinct advantage over biological drugs such as etanercept.   
 In a mouse model of inflammatory liver disease, SSO3274 injected i.p. for 10 days at 
25 mg/kg/day protected the liver from TNF-α insult and prevented liver damage. The 
observed anti-inflammatory effects were likely enhanced by the ability of SSO3274 to 
simultaneously down-regulate TNFR2 while inducing ∆7TNFR2 in the liver. Importantly, 
etanercept administered at a dose comparable to the amount of ∆7TNFR2 induced by 
SSO3274 elicited no such protection. The 10-day dosing regimen also delayed the course of 
disease in a mouse model of collagen-induced rheumatoid arthritis. These results are notable 
given that 30% of rheumatoid arthritis patients do not respond to currently available 
treatments (Olsen and Stein, 2004; Pincus et al., 1999).   
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MyD88 
 MyD88 is an adapter protein that mediates pro-inflammatory cytokine signaling 
through IL-1 and Toll receptors. Upon receptor activation, MyD88 interacts with the receptor 
intracellular domain and recruits IL-1R-associated kinase-1 (IRAK-1) and IRAK-4, leading 
to the phosphorylation of IRAK-1 and the subsequent activation of the transcription factor 
NF-κB. Skipping of the second exon of MyD88 produces naturally occurring splice variant, 
MyD88S. MyD88S retains its receptor binding function but is defective in its ability to recruit 
IRAK-4 and induce IRAK-1 activation; thus, MyD88S functions as a dominant-negative 
regulator of IL-1R and Toll receptor signaling (Janssens et al., 2002). Vickers et al. screened 
20-mer MOE-PS SSOs targeted to the 5′ and 3′ splice sites of exon 2 and selected ISIS 
337846, an SSO that switched splicing from MyD88 to MyD88S in mouse and human cells. 
ISIS 337846 induced redirection of MyD88 mRNA splicing in the liver, adipose tissue, and 
intestine of mice i.p. injected three times per week for three weeks with 50 mg/kg SSO. 
MyD88S protein was not detected, although this could be due to insufficient recognition of 
the splice variant by available antibodies. The SSO regimen abrogated pro-inflammatory IL-
1β signaling in the liver (Vickers et al., 2006).  
HER2  
HER2 is a member of the epidermal growth factor receptor (EGFR) family of 
receptor tyrosine kinases.  EGFR family members are comprised of three functional domains: 
an extracellular ligand-binding domain, a transmembrane domain, and an intracellular 
tyrosine kinase domain.  Ligand-binding to a monomeric receptor promotes homo- or hetero-
dimerization, which leads to auto- or trans-phosphorylation in the cytoplasmic domain and 
downstream signaling, primarily through mitogen-activated protein kinase (MAPK) and 
29 
 
phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathways(Yarden and 
Sliwkowski, 2001).  Therefore, EGFR receptors play critical roles in cell proliferation, 
differentiation and survival (Olayioye et al., 2000).  Deregulation of EGFR receptors has 
been implicated in numerous types of tumors (Hsieh and Moasser, 2007).  HER2 is amplified 
and/or overexpressed in many human malignancies, including 25–30% breast cancers.  
HER2 overexpression correlates with enhanced tumor aggressiveness and decreased patient 
survival.   
The transmembrane domain of HER2 is encoded by a single exon, exon 15. Wan et 
al. screened a series of MOE SSOs and identified one, SSO111, that induced exon 15 
skipping in a sequence-specific, dose-dependent manner, thereby down-regulating full-length 
HER2 while producing a novel splice variant lacking the transmembrane domain, ∆15HER2 
(Wan et al., 2008). In SK-BR-3 human breast cancer cells, which highly express HER2, 
SSO111-induced splice-switching potently inhibited cell growth and induced apoptosis. This 
effect was less pronounced in MCF7 cells, in which HER2 expression is 100-fold lower, 
despite the fact that splice switching was still observed, confirming that SSO111-induced 
growth inhibition was HER2-dependent. This was consistent with the previously reported 
correlation of SSO potency with increased target gene expression (Mercatante et al., 2002). It 
also indicates that tumors highly expressing HER2 would be more sensitive to SSO treatment 
than surrounding healthy tissue. It was further demonstrated that His-tagged ∆15HER2 
protein potently down-regulated HER2 protein expression and inhibited HER3 activation in 
dose-dependent manner in SK-BR-3 cells (Wan et al., 2008).  
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ATM 
Ataxia-telangiectasia (A-T) is an autosomal recessive disorder characterized by 
neurodegeneration, immune defects and predisposition to malignancy. A-T is caused by 
mutations in the ataxia-telangiectasia mutated (ATM) gene, half of which disrupt splicing 
(Teraoka et al., 1999). Recently, 25-mer PMO SSOs were used to block the activation of 
cryptic splice sites in cell lines representing three types of A-T splicing defect: a 5′ exonic 
cryptic splice site in TAT[C] cells, a 3′ exonic cryptic splice site in IRAT9 cells, and a 
pseudoexon inclusion in AT203LA cells (Du et al., 2007). In each case dose-dependent, 
sequence-specific splice correction was achieved, leading to upregulation of functional ATM 
protein. These findings are especially promising in light of evidence that only a small amount 
of functional protein (5-20% wild-type levels) is necessary to significantly ameliorate the 
disease phenotype (Gilad et al., 1998).   
DMD 
Duchenne Muscular Dystrophy is a fatal genetic disease characterized by severe and 
progressive muscle wasting. It is caused by deletions and other mutations in the DMD gene, 
which cause premature termination of translation and result in lack of dystrophin protein. 
Deletions that maintain the reading frame in DMD gene produce internally deleted but 
partially functional dystrophin, causing the milder Becker muscular dystrophy (BMD) 
(Monaco et al., 1988). It has been reported that rare, naturally occurring revertant (i.e. 
dystrophin-positive) fibers are expressed sporadically in muscles tissues of the mdx mouse, a 
mouse model of DMD (Hoffman et al., 1990) and in DMD patients (Nicholson et al., 1989). 
The dystrophin in these revertant fibers consists of internally deleted dystrophin generated by 
omission of the mutated exon through alternative splicing of dystrophin pre-mRNA, resulting 
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in restoration of the translational reading frame of DMD transcripts  (Klein et al., 1992; Lu et 
al., 2000). A goal of DMD research has been to mimic this natural phenomenon to convert 
the DMD phenotype to the BMD phenotype by removing one or more exons to create 
shortened but in-frame dystrophin transcripts generating partially functional dystrophin. This 
approach was validated using SSOs that blocked pre-mRNA splicing elements, thereby 
excluding the mutation-containing exon and restoring the reading frame in DMD transcripts 
in cell-free extracts, (Takeshima et al., 1995), human lymphoblastoid cells (Pramono et al., 
1996), and primary mdx myoblast cultures (Dunckley et al., 1998; Wilton et al., 1999). 
The use of SSOs to induce exon-skipping in DMD has been further validated in 
animal models and clinical trials. The SSO chemistry first used in DMD studies was 2OMe, 
which was tested in primary myoblasts derived from DMD patients carrying different 
deletions and a nonsense mutation (Aartsma-Rus et al., 2003; van Deutekom et al., 2001). In 
mdx mice, which carry a nonsense mutation in exon 23 of the DMD gene, dystrophin 
expression was restored by intramuscular (i.m.) injections of 2OMe SSO targeted to the 5′ 
splice site of intron 23 complexed with cationic liposomes (Mann et al., 2001), or the 
nonionic block copolymer F127 (Lu et al., 2003). In the latter case, SSO treatment led to 
functional improvement of the treated muscle. Because all muscles are affected by DMD, it 
is important to induce dystrophin expression in skeletal, smooth, and cardiac muscles. 
Intravenous injections of 2OMe complexed with F127 induced dystrophin expression in 
body-wide skeletal but not cardiac muscle in mdx mice without detectable toxicity (Lu et al., 
2005).  
Significant progress in DMD research was achieved in mdx mice i.v. injected with 2 
mg uncomplexed PMO SSO at weekly intervals, which led to functional improvement of 
32 
 
tibialis anterior muscles after three injections (Alter et al., 2006). After seven weekly 
injections, levels of dystrophin expression in gastrocnemius and quadriceps of treated mdx 
mice reached 50% normal expression. Additionally, serum creatinine kinase (CK) levels 
were dramatically reduced, suggesting improvement of the underlying disease. The potential 
of PMO SSOs for DMD treatment was further demonstrated in canine X-linked muscular 
dystrophy (CXMD), a clinically severe canine model of DMD. Systemic infusions of PMO 
cocktails inducing skipping of exons 6 and 8 restored dystrophin expression in skeletal 
muscles and ameliorated exercise ability in CXMD canines (Yokota et al., 2008). Other 
chemistries such as LNA, ethylene brdiged nucleic acid (ENA), PNA have been tested in cell 
culture and in vivo but they do not seem to be particularly useful in treatment of DMD 
(Aartsma-Rus et al., 2004; Surono et al., 2004; Yin et al., 2008a). 
Another major advance in exon skipping in DMD has been application of cell 
penetrating peptide-conjugated PMOs (PPMOs). These compounds have shown enhanced 
efficacy in exon 23 removal in mdx mice compared to unconjugated PMO. A PPMO carrying 
(RXR)4XB peptide, (where R is arginine, X is 6-aminohexanoic acid, and B is β-alanine), 
induced normal levels of dystrophin expression in diaphragm and low levels in colon, gut 
and skeletal muscles of mdx mice treated as neonates with four weekly i.p injections at 5 
mg/kg, a significantly lower dose than that used for unconjugated PMO (Fletcher et al., 2007; 
Moulton et al., 2007). However, none of the above studies in animal models showed 
restoration of dystrophin expression in cardiac muscle. Intra-cardiac injections of PMO in 
mdx mice induced only very low level of dystrophin expression (Vitiello et al., 2008). 
Because cardiomyopathy is one of the major causes of death in DMD patients, induction of 
dystrophin expression in cardiac muscle is critical for DMD treatment. Jearawiriyapaisarn 
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and colleagues demonstrated that systemic treatment of mdx mice with PPMO-B carrying 
(RXRRBR)2XB peptide induced in cardiac muscles high levels of exon 23-skipped mRNA 
and produced 20–30% of normal dystrophin protein (Jearawiriyapaisarn et al., 2008). This 
treatment resulted in reduced inflammatory cell infiltration in the heart. Exon 23-skipped 
mRNA and restored dystrophin protein expression remained detectable for at least 2–3 
months after treatment, especially in diaphragm and quadriceps, where 100% exon-skipping 
was maintained. These data suggested that the PPMO-B/PMO is very stable in muscle tissues 
because the half-life of dystrophin mRNA is only about 16 hours (Tennyson et al., 1996). 
The sustained dystrophin expression led to a decrease of serum CK to near wild-type levels, 
confirming that the rescued dystrophin protein was functional. Further study revealed that 
treatment with PPMO-B preserved cardiac sarcolemma integrity and prevented cardiac 
hypertrophy and diastolic dysfunction (Jearawiriyapaisarn et al., 2010). Sustained dystrophin 
expression induced by PPMO-B SSO would be desirable for clinical application due to the 
potential for infrequent re-administration. 
The pre-clinical results described above have led to three clinical trials for 
oligonucleotide-induced exon-skipping in DMD patients. PRO051, a 2OMe SSO targeted to 
an internal sequence of exon 51, was investigated for its ability to induce exon 51 skipping in 
DMD patients (van Deutekom et al., 2007). In this study, a single local i.m. injection of 0.8 
mg PRO051 specifically excluded exon 51 in four DMD patients, thereby restoring the 
translational reading frame. Dystrophin expression equivalent to approximately 3–12% 
normal levels was detected in muscle biopsies taken four weeks after injection. However, 
biopsies from control-treated tissues were not examined making it impossible to determine 
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the background level of dystrophin expression (i.e. from spontaneous revertant fibers) in each 
patient. 
Clinical trials exploring the efficacy of PMO SSOs for DMD are also underway. 
AVI-4658, a PMO SSO that induces exon 51 skipping, was tested in a single-blind, placebo-
controlled, dose-escalation study in patients with deletions in the open reading frame of 
DMD that are responsive to exon 51 skipping. Unlike the PRO051 trial, this study compared 
dystrophin expression in treated muscles with that of saline-injected contralateral muscles, an 
important negative control that accounts for background dystrophin expression.  AVI-4658 
administered i.m. resulted in a 26–32% increase in dystrophin expression locally within 
treated muscles. The level of dystrophin expression is predicted to be sufficient to avoid 
skeletal muscle symptoms (Neri et al., 2007). AVI-4658 was well-tolerated and there were no 
significant drug-related serious adverse events. 
A trial to evaluate systemic administration of AVI-4658 was recently completed. 
Patients received one of six doses ranging from 0.5 to 20 mg/kg once weekly for 12 weeks by 
intravenous infusion. Treatment resulted in substantial dystrophin expression that was related 
to dose, with patients exhibiting up to 55% dystrophin-positive muscle fibers 
(www.avibio.com/ and (Kole, 2010)). CD3, CD4 and CD8 counts, markers of inflammation, 
were reduced, suggesting amelioration of the underlying disease.  The drug was well-
tolerated and there were no drug-related serious adverse events or severe adverse events. 
Data from clinical trials indicating safety of PMOs are consistent with the results from a 
study in cynomolgus monkeys in which AVI-4658 was well-tolerated at the maximum 
feasible dose (320 mg/kg) (Sazani et al., 2010). Still unanswered questions, regarding SSO 
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bioavailability, therapeutic index and long term effects, are being addressed in ongoing pre-
clinical and clinical studies for DMD.  
Summary of the Unique Properties of SSOs 
Modification of pre-mRNA splicing as a therapeutic strategy has several important 
advantages over alternative molecular therapies. Unlike RNase H-sensitive ASOs and 
siRNA, which are limited to down-regulation of target expression, SSOs down-regulate one 
transcript and simultaneously up-regulate the expression of a therapeutic splice variant. 
Importantly, up-regulation of protein expression by SSOs does not alter the DNA in any way; 
this precludes the potential for off-target gene disruptions caused by virus-mediated 
therapies. Furthermore, SSOs induce expression of endogenous proteins, reducing the 
likelihood of stimulating an immune response.  
In the TNFR2 application described earlier, LNA SSO was active primarily in 
hepatocytes, where it induced expression of a soluble secreted decoy receptor that was 
released into systemic circulation (Graziewicz et al., 2008). Cells that take up the SSO are 
thus converted into factories that manufacture the therapeutic splice variant. Because 
synthetic oligonucleotide chemistries such as LNA are resistant to nucleases, SSOs bearing 
these modifications are functionally active in vivo for long periods of time (e.g., 35+ days 
following five 25 mg/kg i.p. injections). SSOs applied in this way would thus require 
relatively infrequent dosing. 
The magnitude of the effect of splice-switching is largely dependent on the level of 
expression of the pre-mRNA transcript. For example, Mercatante et al. found that cells 
expressing higher levels of endogenous Bcl-x were more sensitive to Bcl-x splice-switching 
than cells expressing lower levels. She concluded that cells expressing higher levels of Bcl-x 
36 
 
generated more Bcl-x pre-mRNA that could be converted into pro-apoptotic Bcl-xS, 
rendering them more sensitive to Bcl-x SSO-induced apoptosis (Mercatante et al., 2002). 
This phenomenon provides a layer of target cell specificity because splice-switching will 
have the greatest effect in cells expressing the highest levels of target gene expression. 
Moreover, RNase H-sensitive ASOs and siRNA become less effective as their target gene 
expression increases. This is due to the fact that, as more target mRNA is expressed, 
incomplete repression of target gene expression becomes more consequential. In contrast, 
increased target gene expression enhances the effects of splice-switching strategies.  
Apoptosis  
Apoptosis is the process of programmed cell death marked by distinct morphological 
characteristics and biochemical mechanisms, including DNA fragmentation, chromatin 
condensation, membrane blebbing, cell shrinkage, and disassembly into membrane-enclosed 
vesicles, called apoptotic bodies, which are subsequently engulfed by macrophages and other 
cells (Jacobson et al., 1997; Kerr et al., 1972). This program is essential for normal 
development, maintenance of tissue homeostasis, and immune-system function in 
multicellular organisms. Dysregulation of apoptotic signaling contributes to numerous 
pathological conditions, from degenerative disorders to cancer (Cory and Adams, 2002). 
Indeed, the ability of tumor cells to evade apoptosis is one of the hallmarks of cancer and has 
been the focus of intense research (Adams and Cory, 2007; Hanahan and Weinberg, 2000).  
Caspases 
There are two major apoptotic pathways, the extrinsic or death receptor-mediated 
pathway, and the intrinsic pathway (Figure 1.5). Both pathways converge on the activation of 
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cystein aspartate proteases called caspases, which function in cell disassembly (effectors) and 
in initiating this disassembly in response to pro-apoptotic signals (initiators). Caspases are 
expressed as proenzymes that contain three domains: an NH2-terminal domain, a large 
subunit (~20 kDa) and a small subunit (~10 kDa) (Zimmermann et al., 2001). Activation 
involves proteolytic processing between domains, followed by association of the large and 
small subunits to form a heterodimer. When initiator caspases, such as caspase-8 and -9, are 
activated by oligomerization, they cleave the precursor forms of effector caspases, such as 
caspase-3, -6 and -7. Activated effector caspases in turn cleave a specific set of cellular 
substrates, resulting in the biochemical and morphological changes that characterize the 
apoptosis phenotype (Thornberry and Lazebnik, 1998). One of the targets of caspase 
cleavage is Poly (ADP-ribose) polymerase (PARP), an enzyme involved in single strange 
DNA nick repair (Boulares et al., 1999). The detection of PARP cleavage in cells is 
indicative of an activated caspase cascade. Caspases cleave their cellular targets following an 
aspartic acid; recognition of at least four amino acids downstream of the cleavage is also 
required. The preferred tetrapeptide recognition motif varies among the caspases and 
explains the diversity of their biological function (Thornberry et al., 1997). 
Precisely how the cleavage of cellular substrates causes apoptosis has not been fully 
elucidated. One role caspases play is the destruction of proteins that protect living cells 
against apoptosis. In addition, caspases contribute to cell disassembly by cleaving lamina 
polymers that constitute the rigid structure underlying the nuclear lamina (Takahashi et al., 
1996). In addition, they cleave proteins involved in cytoskeleton regulation (Thornberry and 
Lazebnik, 1998). In many cases, caspases cleave their target such that the substrate protein’s 
regulatory and effector domains are dissociated and thus the function is dysregulated. 
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Examples include proteins involved in DNA repair, mRNA splicing and DNA replication 
(Thornberry and Lazebnik, 1998). In some cases, caspase cleavage creates truncated proteins 
with altered function compared. For example, the anti-apoptotic protein Bcl-2 can be cleaved 
into a truncated form with pro-apoptotic activity (Cheng et al., 1997).   
Extrinsic and Intrinsic Pathways 
The extrinsic pathway is mediated by the so-called death receptors, which include 
members of the TNF receptor family, such as Fas or TNF receptor-1 (TNFR1) (Figure 1.4). 
Binding of ligands such as FASL and TNF to to FAS and TNFR, respectively, recruits the 
adapter protein Fas-associated death domain (FADD) to the intracellular domain of the 
receptors.  FADD mediates activation of caspase-8, which leads to the activation of 
downstream effector caspases (Okada and Mak, 2004). 
 The intrinsic pathway is triggered by intracellular and extracellular stresses, such as 
growth factor withdrawal, hypoxia and DNA damage. Signals that are transduced in response 
to these stresses converge on the mitochondria. A series of biochemical events is induced 
(see next section) that results in the permeabilization of the outer mitochondrial membrane 
(OMM) and the release of pro-apoptotic molecules, including Cytochrome C. Cytochrome C 
binds APAF1 and leads to assembly of a heptameric protein ring called the apoptosome, 
which can bind pro-caspase-9 and induce its activation through a conformational change. 
(Figure 1.5) (Wang, 2001). Permeabilization of the OMM is regulated by the Bcl-2 family of 
proteins, however once cytochrome C is released, the downstream cascade of caspase 
activation is irreversible.   
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Bcl-2 Family of Apoptotic Regulators  
 The Bcl-2 family of apoptotic regulators is divided into three classes, based on 
sequence homology: the pro-apoptotic Bax-like proteins, the anti-apoptotic Bcl-2 homologs, 
and the pro-apoptotic BH3-only proteins (Figure 1.6 A).  
Bax-like Proteins 
 The first class in the Bcl-2 family consists of the pro-apoptotic Bax-like proteins, 
Bax, Bak and Bok (Adams and Cory, 2007). These proteins directly initiate apoptosis by 
oliomerizing at the mitochondrial membrane, leading to a change in the outer mitochondrial 
membrane potential. This results in membrane permeabilization and consequent efflux of 
pro-apoptotic factors, such as cytochrome C.  
Bax and Bak contain four Bcl-2 homology (BH) domains BH1, BH2, BH3 and BH4, 
whereas Bok has BH domains 1-3, but lacks BH4 (Figure 1.6 A). All three Bax-like proteins 
encode C-terminal hydrophobic regions that enable them to associate with the OMM. 
Structural analysis indicates that the BH1, -2 and -3 domains form a hydrophobic groove that 
form a binding pocket for the BH3-domain of other Bcl-2 family proteins. In addition, in its 
inactive conformation, the C-terminal membrane anchor domain of Bax fits into its own 
BH1–3 hydrophobic pockets and Bax resides in the cytosol. (Nechushtan et al., 1999). 
Bax and Bak may have some redundancy of function, as loss of either gene has little 
effect in most cells and tissues. However, absence of both genes completely blocks apoptosis 
in many cell types (Wei et al., 2001b), and results in drastic developmental defects and 
typically perinatal death (Lindsten et al., 2000). While Bax and Bak are widely expressed, 
Bok expression is restricted to ovary, testis and uterus; it does not appear to play as crucial a 
role in apoptotic signaling (Hsu et al., 1997).  
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In non-apoptotic cells, Bak is associated with the mitochondrial membrane and Bax is 
present in the cytosol with its C-terminal membrane-anchoring domain sequestered in its own 
BH1–3 hydrophobic pocket. Apoptotic stimuli prompt a conformational change in Bax 
causes its translocation to the mitochondria and exposes its C-terminal hydrophoic tail, which 
enables it to associate with the OMM (Nechushtan et al., 1999). Because Bak is already 
present at the OMM, it may be keep inactive by interaction with anti-apoptotic Bcl-2 family 
members (Cuconati et al., 2003). 
Anti-apoptotic Proteins 
 The anti-apoptotic Bcl-2 family members include Bcl-2, Bcl-xL, Mcl-1L, Bcl-w and 
Bfl-1/A1. Bcl-2, Bcl-xL and Bcl-w each have all four BH domains, Mcl-1L has BH domains 
1, 2 and 3 and Bfl-1/A1 has only BH domains 1 and 2 (Figure 1.5 A).  As in the Bax-like 
proteins, BH domains 1–3 form a hydrophobic binding pocket that serves as a binding site 
for the BH3 domains of other Bcl-2 family proteins. In addition, Bcl-2, Bcl-xL, Bcl-w and 
Mcl-1L each have a C-terminal hydrophobic domain, which is responsible for membrane 
localization.  
The anti-apoptotic Bcl-2 proteins prevent cells from committing to apoptosis by 
interacting with and antagonizing Bax and Bak proteins (Adams and Cory, 2007). Bax can 
form heterodimers via its BH3 domain with all five major anti-apoptotic Bcl-2 homologs, 
suggesting that all the anti-apoptotic family members participate in Bax regulation. Bak 
forms heterodimer with Mcl-1L and Bcl-xL, however it appears to bind Mcl-1L with several 
fold higher affinity than Bcl-xL (Willis et al., 2005). Bcl-2 does not appear to play a role in 
regulating Bak (Willis et al., 2005). 
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 Three additional putative anti-apoptotic Bcl-2 family proteins, Bcl-RAMBO, Bcl-B, 
and Bcl-G, contain multiple BH domains and share high sequence homology with other Bcl-
2 family members. However, they are less well studied and as a result their roles in apoptosis 
have not been elucidated (Youle and Strasser, 2008).   
BH3-only Proteins 
The third class of the Bcl-2 family is comprised of the BH3-only proteins and 
includes Bad, Bid, Bim, Bmf, Bik, Hrk, Noxa and Puma. As their name suggests, these 
proteins each contain a BH3 domain, but they are otherwise largley unrelated in sequence to 
either Bcl-2 or each other (Willis and Adams, 2005) (Figure 1.5 A). The BH3 domain is 
required for their pro-apoptotic activity and is involved in binding pro-survival Bcl-2 family 
members at the OMM (Chang et al., 1999; Petros et al., 2004). 
The BH3-only proteins promote apoptosis upon activation by pro-apoptotic signals. 
Puma and Noxa are transcriptionally up-regulated in a p53-dependent manner in response to 
DNA damage (Nakano and Vousden, 2001; Oda et al., 2000). Noxa is also transcriptionally 
activated by c-MYC in response to proteasome inhibition (Nikiforov et al., 2007).  Bim 
expression is activated by the transcription factors FOXO3A and CEBPα in response to 
growth factor deprivation (Dijkers et al., 2000) and endoplasmic reticulum stress 
(Puthalakath et al., 2007), respectively. Bad is dephosphorylated in response to growth factor 
deprivation, causing its release from 14-3-3 proteins and translocation to the mitochondria 
(Zha et al., 1996). Two splice variants of Bim, BimEL and BimL, are sequestered in inactive 
conformations at the microtubules-associated dynein complex in healthy cells. Likewise, 
Bmf is sequestered to myosin V motors by association with dynein light chain 2.  Apoptotic 
stimuli such as serum withdrawal or anoikis prompt the translocation of BimEL, BimL and 
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Bmf to the mitochondria. Bid normally exists in the cytosol in its full-length inactive form. 
Death receptor activation activates caspase-8, which then cleaves Bid into its truncated, 
active form, tBid, which translocates to the mitochondria (Li et al., 1998). Bid thus provides 
a means for crosstalk between the death receptor-mediated and mitochondrial death 
pathways. 
The BH3-only proteins exhibit widely varying binding affinities for the anti-apoptotic 
Bcl-2 proteins (Chen et al., 2005). For example, PUMA binds Bcl-2, Bcl-xL, Mcl-1L and Bcl-
w with high affinity, whereas NOXA binds only Mcl-1L with high affinity (Adams and Cory, 
2007).  Likewise, the anti-apoptotic Bcl-2 homologs bind Bax and Bak with different 
affinities. Both Bim and tBid appear to have affinity for Bcl-2 (Opferman et al., 2005). 
Indirect Activation of Apoptosis by BH3-only Proteins 
Activation of BH3-only proteins does not trigger apoptosis in cells lacking Bak and 
Bax, indicating that they act upstream of Bax and Bak (Cheng et al., 2001). Apoptotic stimuli 
trigger conformational changes in Bax and Bak and prompt their localization to and 
oligomerization at the OMM. At the OMM, however, Bax and Bak are bound by the anti-
apoptotic Bcl-2 homologs, sequestering them and preventing oligomerization. A 
preponderance of evidence indicates that activated BH3-only proteins induce apoptosis by 
competing with Bax/Bak for binding with the anti-apoptotic Bcl-2 homologs, thereby 
displacing Bax/Bak and freeing them to oligomerize at the OMM  (Figure 1.5 B)(Chen et al., 
2005; Lacerra et al., 2000; Willis et al., 2005; Willis et al., 2007). In this model, BH3-only 
proteins act as damage sensors that indirectly trigger apoptosis by directly antagonizing the 
anti-apoptotic Bcl-2 proteins (Adams and Cory, 2007).There is some evidence that certain 
BH3-only proteins can directly activate apoptosis, as Bim and tBid have been shown to 
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synergize with Bax in cell-free membrane permeabilization assays (Lacerra et al., 2000). 
However, this concept has been called into question by the inability to definitively show 
direct interactions between Bid, tBid or Bim with Bax or Bak, and by the observation that 
apoptosis is not abrogated in Bim/Bid double knock mice (Willis et al., 2007).  
Bcl-2 Family in Cancer 
 The balance of BH3-only and anti-apoptotic Bcl-2 proteins determines whether the 
cell will commit to apoptosis. Up-regulation of the anti-apoptotic Bcl-2 homologs, enables 
them to overcome antagonism by BH3-only proteins, inhibiting apoptosis. Consequently, 
overexpression of an anti-apoptotic family member, or loss of a pro-apoptotic relative can be 
oncogenic. Because many chemotherapeutic drugs induce apoptosis through activation of 
BH3-only proteins, the overexpression of Bcl-2 anti-apoptotic proteins promotes 
chemoresistance (Huang and Strasser, 2000). A screen of somatic copy-number profiles from 
3,131 cancers across more than two dozen cancer types found that the bcl-x and mcl-1 genes 
were amplified with significant frequency suggesting that up-regulation expression of these 
genes may be a common mechanism for cancers to increase survival (Beroukhim et al., 
2010).  
Due to their roles in cancer progression and chemoresistance, the anti-apoptotic Bcl-2 
homologs are the targets of numerous inhibitors in clinical development (Storey, 2008). For 
example, the small molecule ABT-737 binds Bcl-2, Bcl-xL and Bcl-w proteins with 
nanomolar affinity. It induced apoptosis in lymphoma and small-cell lung carcinoma cells in 
culture, and caused tumor regression and improved survival in preclinical studies (Oltersdorf 
et al., 2005). An orally bioavailability analog of ABT-737, ABT-263, is currently in Phase 
I/II clinical trials to evaluate its single agent efficacy for refractory chronic lymphocytic 
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leukemia, refractory lymphoid malignancies, and advanced small cell lung cancer 
(www.clinicaltrials.gov). Another small molecule, GX015-070, binds Mcl-1 with high 
affinity. This agent induced apoptosis in multiple myeloma cells (Trudel et al., 2007) and 
showed antitumor activity in mouse tumor xenografts derived from colon, prostate and 
cervical cancer cells (Nguyen et al., 2007). GX015-070 is currently being evaluated 
combination therapy in Phase II clinical trials for refractory multiple myeloma and refractory 
and advanced-stage small cell lung cancer (www.clinicaltrials.gov). Clearly, pharmacological 
agents that promote apoptosis by affecting the Bcl-2 family hold promise as potential anti-
cancer therapeutics.  
Bcl-x 
 The Bcl-x gene contains three exons, the first of which is untranslated. Its pre-mRNA 
transcript undergoes alternative splicing at the 5′ splice site of exon 2 to produce protein 
isoforms with opposing functions, Bcl-xL (long) and Bcl-xS (short). A third isoform, Bcl-xβ, 
results from an unspliced transcript (Ban et al., 1998; Gonzalez-Garcia et al., 1994). Bcl-x is 
widely expressed in human and mouse (Gonzalez-Garcia et al., 1995; Gonzalez-Garcia et al., 
1994; Krajewski et al., 1994). Bcl-xL is widely expressed, particularly in tissues containing 
long-lived post-mitotic cells such as adult brain. Bcl-xβ has not been well-studied, however 
one study in mouse suggested that its patter of expression is similar to that of Bcl-xL, albeit at 
lower levels (Gonzalez-Garcia et al., 1995). In neurons, Bcl-xβ protected cells against 
apoptosis (Gonzalez-Garcia et al., 1995), while rat Bcl-xβ promoted apoptosis in promyeloid 
cells (Shiraiwa et al., 1996). Bcl-xS is expressed in cells that undergo high rate of turnover, 
such as developing lymphocytes (Boise et al., 1993).   
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Splicing at the downstream (Bcl-xL) alternative splice produces the major isoform, 
Bcl-xL (Boise et al., 1993). Bcl-xL is a anti-apoptotic Bcl-2 homolog that contains all four BH 
domains (BH1-BH4) and a C-terminal hydrophobic region responsible for localization to the 
OMM. It promotes cell survival by binding and sequestering Bak and Bax with high affinity. 
Bcl-xL expression also induces the proangiogenic interleukin-8 (IL-8) and chemokine (C-X-
C motif) ligand 1 (CXCL1) in vitro and in vivo (Giorgini et al., 2007; Karl et al., 2007). 
Increased expression of Bcl-xL enables tumor cells to evade apoptosis and promotes 
resistance to a broad range of chemotherapeutic agents (Amundson et al., 2000). Not 
surprisingly, Bcl-xL overexpression has been detected in multiple myeloma (Tu et al., 1998), 
small cell lung carcinoma (Reeve et al., 1996), breast cancer (Olopade et al., 1997), prostate 
cancer (Castilla et al., 2006; Mercatante et al., 2002), metastatic melanoma (Tang et al., 
1998), hepatocellular carcinoma (HCC) (Takehara et al., 2001; Watanabe et al., 2002), and 
colorectal cancer (Backus et al., 2002). Downregulation of Bcl-xL using 2OMe gapmer ASOs 
sensitized colon cancer cells to ionizing radiation (Wacheck et al., 2003). Likewise, Bcl-x 
ASOs triggered apoptosis in HCC cells (Takehara et al., 2001). 
Use of the upstream (Bcl-xS) 5′ alternative splice site of Bcl-x exon 2 produces Bcl-xS 
(Boise et al., 1993). Bcl-xS lacks 189 bases from the C-terminal end of exon 2, though the 
reading frame is maintained; as a result Bcl-xS encodes only the BH3 domain. Exogenous 
expression of Bcl-xS was found to inhibit the ability of Bcl-2 and Bcl-xL to protect cells from 
apoptotic stimuli (Boise et al., 1993; Minn et al., 1996) in a BH3 domain-dependent manner 
(Chang et al., 1999). Bcl-xS was also found to directly bind Bcl-xL and Bcl-2 (Minn et al., 
1996; Sato et al., 1994). Thus, Bcl-xS is thought to act as a pro-apoptotic BH3-only protein, 
indirectly inducing apoptosis through antagonism of Bcl-xL and Bcl-2 (Willis et al., 2007). 
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Conditional expression of Bcl-xS under the control of a Tetracycline-inducible promoter 
reduced the growth of human melanoma tumor xenografts (Hossini et al., 2003).   
Regulation of Bcl-x Alternative Splicing 
Several studies have been published describing regulation of Bcl-x alternative 
splicing (summarized in Figure 1.7). F and H hnRNP proteins were found to bind 10–30 
nucleotides downstream of the Bcl-xS alternative splice site. Addition of these proteins to 
HeLa cell extract stimulated Bcl-xS expression and their abolition by siRNA reduced Bcl-xS 
expression in cells in culture (Garneau et al., 2005).  
The lipid molecule ceramide, a regulator of various stress responses and growth 
mechanisms, was found to direct Bcl-x splicing from Bcl-xL to -xS in a protein phosphatase 1 
(PPN1)-dependent manner (Chalfant et al., 2002).  The chemotherapeutic nucleoside analog 
gemcitabine shifted splicing from Bcl-xL to -xS splicing via induction of ceramide lipid 
synthesis in A549 lung cancer cells. This activity involves the splicing factor SAP155, which 
binds a ceramide-responsive cis-element, CRCE1, upstream of the Bcl-xS splice site 
(Massiello et al., 2006).   
The RNA-binding protein Sam68 has also been implicated in the regulation of Bcl-x 
alternative splicing. Depletion of Sam68 led to the accumulation of Bcl-xL whereas Sam68 
upregulation led to increased expression of Bcl-xS (Paronetto et al., 2007). Tyrosine 
phosphorylation of Sam68 by the Fyn kinase, a Src-like tyrosine kinase, inverted this effect 
and favored usage of the Bcl-xL splice site. Overexpression of the splicing factor SF2/ASF 
blocked Bcl-xS expression by Sam68. In addition to Bcl-x, Sam68 was found to bind 
endogenous mRNAs of Bak, Bax, and Bim.  
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The transcription factor E2F1 plays a key role during S phase progression and 
apoptosis. Among the transcriptional targets of E2F1 is sc35, a component of the 
spliceosome. Expression of E2F1 under the control of an inducible promoter activated the 
Bcl-xS splice site in an SC35-dependent manner (Merdzhanova et al., 2008). This effect was 
recapitulated in cells treated with DNA damaging agents, which induced E2F1 
transactivation of sc35 and a shift in Bcl-x alternative splicing from Bcl-xL to -xS.  
 The splicing factor RBM25 was found to activate the Bcl-xS splice site binding an 
ESE (CGGGCA) situated 64–69 nucleotides upstream of the Bcl-xS splice site and 
associating with hLuc7A, a U1 snRNP-associated factor (Zhou et al., 2008). RBM25 thereby 
facilitates recruitment of U1 snRNP to and subsequent spliceosome assembly at the weaker 
Bcl-xS splice site. 
In addition to the regulators of Bcl-x alternative splicing enumerated above, there are 
likely many more that remain to be identified. Control of Bcl-x alternative splicing is thus 
complex, with multiple exonic and intronic control elements that allow Bcl-x splicing to 
respond differently to a variety of signals in distinct cellular contexts.  
Direction of Bcl-x Alternative Splicing with SSOs 
Previously, our lab applied SSOs to switch the pattern of Bcl-x pre-mRNA splicing 
from anti-apoptotic Bcl-xL to pro-apoptotic Bcl-xS. Mercatante et al. used 2OMe SSOs 
targeted to the Bcl-xL splice site and demonstrated that this resulted in a dose-dependent and 
sequence-specific manner that induced apoptosis in PC-3 and Mcf-7 cells (Mercatante et al., 
2001). Importantly, modulation of splicing was more effective at inducing apoptosis than 
antisense-mediated down-regulation of Bcl-xL. Bcl-x splice-switching also sensitized cells to 
treatment with γ-irradiation and chemotherapeutic drugs, including etoposide, 5-fluorouracil, 
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cisplatin, 5-fluorodeoxyuridine and doxorubicin. Subsequent study revealed that sensitivity 
to SSO-induced apoptosis correlated with the level of endogenous Bcl-xL expression 
(Mercatante et al., 2002), presumably due to the cell’s dependence on the anti-apoptotic 
activity of Bcl-xL for survival. Moreover, higher Bcl-xL expression also provides more pre-
mRNA that can be converted into pro-apoptotic Bcl-xS, which antagonizes both Bcl-xL and 
Bcl-2. Thus, cancers with high Bcl-xL expression, and those that depend on Bcl-xL 
expression for survival, represent good candidates for treatment with SSOs targeting Bcl-x 
(Mercatante et al., 2002).  
Another group used MOE SSOs to modify Bcl-x splicing in A549 lung cancer cells, 
sensitizing them ultraviolet B radiation and cisplatin (Taylor et al., 1999). Wilusz et al. 
targeted Bcl-x for splice-switching using a chimeric PNA oligonucleotide conjugated to a 
polypeptide containing eight Ser-Arg repeats (Wilusz et al., 2005). This compound shifted 
Bcl-x splicing and induced apoptosis in HeLa cells, recapitulating the findings of Mercatante 
and colleagues.  
Based on the in vitro studies described above, modification of Bcl-x splicing holds 
promise as an anti-cancer strategy; however, the effects of Bcl-x splice-switching has yet to 
be evaluated in a more realistic in vivo setting. The in vivo effect of Bcl-x splice-switching 
was addressed in Specific Aim 1 of this dissertation. 
Mcl-1  
 Mcl-1 is an immediate-response gene that is widely expressed in human tissues and is 
required for survival of hematopoietic stem cells (Opferman et al., 2005) and myeloid cells 
(Edwards et al., 2004).  Mcl-1 expression is rapidly induced in response to signals for cell 
differentiation, including granulocyte-macrophage colony-stimulating factor, stem cell factor 
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and interleukin (IL)-3, IL-5, IL-6, IL-7 and IL-15 in various cell types (Warr and Shore, 
2008; Wei et al., 2001a). Expression is also induced in response to certain cytotoxic agents, 
including colchicine and vinblastine (Yang et al., 1996). Mcl-1 mRNA is  rapidly turned 
over, with a half-life between 30 min and a few hours depending on the cell type and culture 
conditions (Nijhawan et al., 2003; Yang et al., 1996).  
Mcl-1 pre-mRNA consists of three exons which are alternatively spliced to produce a 
longer isoform, Mcl-1L, encoding all three exons, and a short form, Mcl-1S, encoding only 
exons 1 and 2 (Bae et al., 2000; Bingle et al., 2000). Mcl-1L is the predominant isoform while 
Mcl-1S expression is absent or very low in healthy adult cells (Bae et al., 2000; Bingle et al., 
2000; Legartova et al., 2009).  The first 229 amino acids are identical in Mcl-1L and -1S; 
however, due to skipping of exon 2, Mcl-1S contains a novel 42-amino acid C-terminus. Both 
proteins encode PEST domains (sequences rich in proline, glutamic acid, serine and 
threonine) near the N-terminus, which are associated with high-turnover proteins (Bae et al., 
2000; Bingle et al., 2000). As described earlier, Mcl-1L encodes BH domain 1−3, which form 
a hydrophobic pocket that serves as a binding site for the BH3 domain of other Bcl-2 family 
members. Pro-apoptotic Bak binds at this site via its BH3 domain, inhibiting Bak-mediated 
apoptosis (Willis et al., 2005; Zhai et al., 2008). The rapid up-regulation of Mcl-1 gene and 
Mcl-1L protein expression in response to cytokines, coupled with its rapid turnover suggest 
that Mcl-1L provides short-term protection against cell death during critical transitions in cell 
fate (Craig, 2002). 
Certain apoptotic stimuli, such as DNA damage by etoposide or UV irradiation, 
prompt Mcl-1L ubquitination by Mule/Arf-BP1 E3 ligase and subsequent proteasomal 
degradation (Zhong et al., 2005). Elimination of Mcl-1L, by decreased transcription or 
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proteasomal degradation, is an early and required step for apoptosis induced by DNA 
damaging agents, including UV irradiation, cisplatin and etoposide (Nijhawan et al., 2003).  
The deubiquitinase USP9X stabilizes Mcl-1L and promotes tumor survival (Schwickart et al., 
2010).  
In a manner similar to Bcl-xL, overexpression of Mcl-1L enables tumor cells to resist 
apoptosis and has been reported in a number of malignancies, including multiple myeloma 
(Zhang et al., 2002), acute myeloid leukemia (Konopleva et al., 2006), melanoma (Boisvert-
Adamo et al., 2009), cervical cancer (Wei et al., 2001a) and poor-prognosis breast cancer 
(Ding et al., 2007). Amplification of the Mcl-1 gene was found to be significantly enriched in 
a broad range of cancers, suggesting a general role for its predominant splice variant, Mcl-1L, 
in cancer pathogenesis. Cancer cell lines insensitive to ABT-737, a small molecule inhibitor 
of Bcl-2, Bcl-xL and Bcl-w, were found to express high levels of Mcl-1L (Tahir et al., 2007). 
Down-regulation of Mcl-1L was required to sensitize resistant cells to ABT-737 (Chen et al., 
2007; Tahir et al., 2007; van Delft et al., 2006). Chronic treatment of SCLC cells with ABT-
737 led to a progressive decrease in Bcl-2 and Noxa levels, and a concomitant increase in 
Mcl-1L levels (Tahir et al., 2007). Knock-down of Mcl-1 deubiquitinase USP9X increases 
Mcl-1 polyubiquitination, which enhances Mcl-1 turnover and sensitivity to ABT-737. Taken 
together, these findings indicate an important role for Mcl-1L in the development and 
chemoresistance of a broad range of cancers. Importantly, Mcl-1L appears to at least partially 
compensate for loss of other anti-apoptotic Bcl-2 proteins. 
 Because skipping of exon 2 causes a shift in the reading frame, Mcl-1S encodes only 
the BH3 domain and thus resembles a BH3-only protein. Mcl-1S was found to bind Mcl-1L in 
a yeast two-hybrid assay and its overexpression induced apoptosis in CHO cells (Bae et al., 
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2000; Bingle et al., 2000). Mcl-1L was found to completely counteract Mcl-1S-induced 
apoptosis in CHO cells, while Bcl-xL and Bcl-w could only partially counteract this effect 
(Bae et al., 2000). Little is known about the regulation of Mcl-1S, but it may play a role 
during developmental stages or in high turnover cell types. For example, it was up-regulated 
under hypoxic conditions in placental cells (Soleymanlou et al., 2007).  
In summary, Mcl-1 pre-mRNA undergoes alternative splicing to produce splice 
variants with opposing functions in the regulation of apoptosis. A shift in Mcl-1 pre-mRNA 
splicing from Mcl-1L to -1S would be expected to induce apoptosis and/or render tumor cells 
more sensitive to chemotherapeutics. Mcl-1 thus constitutes an ideal target for SSOs. 
Dissertation Specific Aims 
Specific Aim 1: Experiments in Aim 1 were designed to test the hypothesis that 
redirection of Bcl-x pre-mRNA splicing from Bcl-xL to -xS could elicit pro-apoptotic effects 
in melanoma cells and tumor xenografts. Experimental results support this hypothesis and are 
discussed in chapter 2.  
Specific Aim 2: Experiments in specific aim 2 were designed to test the hypothesis 
that the alternative splicing pattern of Mcl-1 pre-mRNA can be shifted using SSOs targeted 
to the 5 ′ or 3′ splice site of alternatively spliced exon 2. Additional experiments in aim 2 
were designed to test the hypothesis that redirection of Mcl-1 pre-mRNA splicing induces 
apoptosis and/or sensitizes cells to chemotherapeutic agents. Experimental results that 
support these aims are discussed in chapter 3. 
Results of both aims are briefly summarized in chapter 4 and future studies are 
proposed. Progress in the development oligonucleotide therapeutics is also discussed.  
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Figure 0.1 Schematic representation of pre-mRNA splicing.  
(A) Schematic exon-intron-exon structure. The conserved pre-mRNA sequences involved in 
splicing are shown, including the 5′ splice site (ss), branch point, polypyrimidine tract 
(Yn<10), and 3′ splice site and splicing regulatory elements (ESE, ISS, ISE and ESS). Y 
denotes either pyrimidine base, R denotes either purine base, N denotes any base. (B) Pre-
mRNA splicing proceeds via two consecutive transesterification reactions. The first 
transesterification reaction is triggered by the 2′-OH of the branch point A. This group acts as 
a nucleophile to attack the phosphoryl group of the conserved G in the 5′ splice site. As a 
consequence, the phosphodiester bond between the sugar and the phosphate at the junction 
between the intron and the exon is cleaved and the freed 5′ end of the intron is joined to the A 
within the branch site. Thus, in addition to the 5′ and 3′ backbone linkages, a third 
phosphodiester extends from the 2′-OH of the A to create a three-way junction. The 5′ exon 
is a leaving group in the first reaction. In the second reaction, the newly liberated 3′-OH of 
the 5′ exon reverses its role and becomes a nucleophile that attacks the phosphoryl group at 
the 3′ splice site. This reaction joins the two exons and releases the intron as a lariat.  
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Figure 0.2 Examples of patterns of alternative splicing.  
(A) Exon skipping. (B) Alternative 5’ splice site. (C) Intron retention. (D) Mutually exclusive 
exons. (E) Alternative start sites. (F) Alternative polyadenylation sites. 
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Figure 0.3 Synthetic oligonucleotide chemistries useful for splice-switching applications. 
R denotes H or S (for phosphorothioate). (A) DNA phosphorothioate. Phosphorothioate (PS) 
internucleotide linkages greatly increase resistance to nuclease degradation, rendering PS 
oligonucleotides stable in plasma, tissues and cells. The PS modification can be used in 
combination with 2′-modifcations; however PS alone does not confer RNAse H resistance. 
(B) 2′-O-methyl (OMe) oligoribonucleotide. (C) 2′-O-methoxyethyl (MOE) 
oligoribonucleotide. The 2OMe and MOE 2'-modifications confer increased binding affinity 
and enhance nuclease resistance, including RNAse H non-competence. (D) Locked nucleic 
acid (LNA). The LNA modification confers dramatically increased binding affinity and 
improved nuclease resistance, including RNAse H non-competence. (E) Phosphorodiamidate 
morpholino (PMO). The PMO backbone modification confers nuclease resistance, including 
RNAse H non-competence; however, PMO oligonucleotides are neutral and thus have 
difficulty crossing cell membranes unaided. (F) Peptide nucleic acid (PNA). The PNA 
modification confers increased binding affinity and nuclease resistance, including RNAse H 
non-competence. Like PMO, PNA oligonucleotides are neutral and thus have difficulty 
crossing cell membranes.  
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Figure 0.4 Applications of splice-switching oligonucleotides (SSOs) 
SSOs can be applied to correct aberrant splicing, to modify alternative splicing to up-regulate 
an existing splice variant, or two modify pre-mRNA splicing to induce expression of a novel 
splice variant. (A) Correction of aberrant splicing of ATM gene transcripts leads to 
production of functional ATM protein (Du et al., 2007). (B) Manipulation of Bcl-x 
alternative splicing switches production from anti-apoptotic Bcl-xL to pro-apoptotic Bcl-xS. 
See text for details (Mercatante et al., 2001). (C) Production of a novel splice variant, 
∆15HER2, which is a soluble decoy receptor (Wan et al., 2008). 
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Figure 0.5 Scheme depicting mitochondrial (intrinsic) and death receptor-mediated 
(extrinsic) pathways of apoptosis. 
Apoptosis can be induced by various genotoxic agents, metabolic insults or transcriptional 
cues (mitochondrial pathway) or by cell surface receptors, such as Fas and TNFR2 (death 
receptor-mediated pathway). The mitochondrial pathways is initiated when apoptotic stimuli 
activate BH3-only members of the Bcl-2 family, which indirectly induce apoptosis through 
antagonism of anti-apoptotic Bcl-2 proteins. See text for details. 
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Figure 0.6 Regulation of apoptosis by Bcl-2 family proteins. 
The Bcl-2 family regulates apoptosis via the mitochondrial pathway. (A) The Bcl-2 family is 
comprised of three subfamilies. The anti-apoptotic Bcl-2 homologs encode multiple basic 
helix (BH) domains. The pro-apoptotic Bax-like proteins contain BH domains 1-3. Finally, 
the pro-apoptotic BH-3 only proteins encode only the BH3 domain. (B) Upon activation by 
apoptotic stimuli, Bax and Bak proteins oligomerize at the outer mitochondrial membrane 
(OMM), causing membrane destabilization and efflux of pro-apoptotic factors such as 
cytochrome C. The anti-apoptotic Bcl-2 homologs block apoptosis by binding and 
antagonizing Bax and Bak. Apoptotic stimuli activate BH3-only protein, which indirectly 
induce apoptosis by binding and antagonizing the anti-apoptotic Bcl-2 homologs. 
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Figure 0.7 Regulation of Bcl-x alternative splicing. 
Splicing at the downstream or upstream 5′ alternative splice site of exon 2 produces Bcl-xL or 
Bcl-xS, respectively. The RNA-binding protein SAP155 binds the CRCE1 element and 
inhibits splicing at the Bcl-xS splice site. Gemcitabine-induced ceramide indirectly activates 
Bcl-xS splicing by repressing SAP155. RBM25 and hnRNP F/H proteins bind exonic splicing 
enhancer elements and activate the Bcl-xS splicing. The RNA-binding protein Sam65 
activates Bcl-xS splicing. This activity is inhibited by SF2/ASF and phosphorylation by Fyn 
kinase; it is induced by hnRNP A1. Bcl-xS splicing is also activated by SC35, under 
transcriptional regulation of E2F1.  
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Chapter 2 – Modification of splicing and anti-tumor effects of Bcl-x splice-switching 
oligonucleotides in vivo 
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Abstract 
 Alternative splicing has emerged as an important target for molecular therapies. 
Splice-switching oligonucleotides (SSOs) modulate alternative splicing by hybridizing to 
pre-mRNA sequences involved in splicing and blocking access to the transcript by splicing 
factors. Recently, the efficacy of SSOs has been established in various animal disease 
models; however, the application of SSOs against cancer targets has been hindered by poor 
in vivo delivery of antisense therapeutics to tumor cells.  The apoptotic regulator Bcl-x is 
alternatively spliced to express anti-apoptotic Bcl-xL and pro-apoptotic Bcl-xS. Bcl-xL is up-
regulated in many cancers and is associated with chemoresistance, distinguishing it as an 
important target for cancer therapy. Out lab previously showed that redirection of Bcl-x pre-
mRNA splicing from Bcl-xL to -xS induced apoptosis in breast and prostate cancer cells. In 
this study, the effect of SSO-induced Bcl-x splice-switching on metastatic melanoma was 
assessed in cell culture and B16F10 tumor xenografts. SSOs were delivered in vivo using 
lipid nanoparticles. Administration of nanoparticle with Bcl-x SSO resulted in modification 
of Bcl-x pre-mRNA splicing in lung metastases and reduced tumor load, while nanoparticle 
alone or formulated with a control SSO had no effect. Our findings demonstrate in vivo anti-
tumor activity of SSOs that modulate Bcl-x pre-mRNA splicing. 
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Introduction 
Over 90% of multi-exon pre-mRNA transcripts undergo alternative splicing (Wang et 
al., 2008) and up to one-half of disease-causing mutations affect splicing (Lopez-Bigas et al., 
2005). Thus, in addition to its significant contribution to proteome diversity, alternative 
splicing constitutes an important therapeutic target (Cooper et al., 2009). Slice-switching 
oligonucleotides (SSOs) modulate alternative splicing by hybridizing to pre-mRNA 
sequences involved in splicing and blocking access by various splicing factors (Dominski 
and Kole, 1993; Sierakowska et al., 1996). Unlike siRNA and traditional antisense 
approaches, which lead to RNA degradation by RISC and RNase H-mediated cleavage, 
respectively, direction of pre-mRNA splicing requires that the SSO-targeted RNA is not 
degraded. This is achieved by altering the oligonucleotide sugar-phosphate backbone as in, 
for example, the 2′-O-methoxyethyl (MOE) ribose modification (Sazani et al., 2003; Sazani 
et al., 2001). In order to realize their full therapeutic utility, SSOs must be efficiently 
delivered to the pharmacological site of action in vivo (Juliano et al., 2009b). This can be 
achieved by exploiting the inherent pharmacodynamic properties of the SSO chemistry 
(Graziewicz et al., 2008; Sazani et al., 2002), conjugation of cell penetrating peptides 
(Jearawiriyapaisarn et al., 2008; Svasti et al., 2009; Wu et al., 2008), and the use of 
nanoparticle carriers (Rimessi et al., 2009).  As a result, in vivo efficacy has been established 
for SSOs in animal models of inflammatory disease, β-thalassemia, and Duchenne muscular 
dystrophy (DMD) [For a recent review, see (Bauman et al., 2009)], and early phase clinical 
trials using SSOs to treat DMD have yielded promising results (Kinali et al., 2009; van 
Deutekom et al., 2007).   
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Previously, this laboratory and others applied SSOs to manipulate the splicing pattern 
of the apoptotic regulator Bcl-x. Through alternative splicing, the Bcl-x gene yields two 
major protein isoforms with opposing functions, anti-apoptotic Bcl-xL and pro-apoptotic Bcl-
xS (Boise et al., 1993) (Figure 1A). Bcl-xL is up-regulated in a number of cancers and confers 
resistance to a broad range of chemotherapeutic drugs (Amundson et al., 2000). Bcl-xS 
antagonizes the anti-apoptotic activity of Bcl-xL and another anti-apoptotic protein, Bcl-2 
(Lindenboim et al., 2001; Minn et al., 1996). Redirection of Bcl-x splicing from Bcl-xL to -xS 
induced apoptosis and increased chemosensitivity in cancer cells in culture (Mercatante et al., 
2001; Mercatante et al., 2002; Taylor et al., 1999); however, the anti-tumor effect of this 
strategy remains to be demonstrated in vivo.   
Because the SSO effectively converts Bcl-xL to Bcl-xS, cancers expressing high levels 
of Bcl-xL represent good candidates for treatment with Bcl-x SSO (Mercatante et al., 2002). 
Metastatic melanoma is an aggressive malignancy with poor prognosis and disease 
progression is associated with increased Bcl-xL expression (Leiter et al., 2000; Zhuang et al., 
2007). Xenografts of murine B16F10 melanoma cells provide a good model of this 
aggressive cancer because they express Bcl-xL and are syngeneic to C57BL/6 mice, obviating 
the need for immunocompromised animals and providing a more realistic environment for 
drug testing. In this model, B16F10 murine melanoma cells localize to the lungs shortly after 
injection into the tail vein, providing a concise and predictable experimental time-course. In 
addition, the cell line used here expressed luciferase, providing an easily quantified measure 
of the tumor load. We previously failed to detect activity of systemically-delivered free SSOs 
in tumor xenografts. Thus, for this work we employed a liposome-DNA-polycation (LPD) 
nanoparticle (NP) formulation designed by the Huang laboratory (Li et al., 2008a; Li and 
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Huang, 2006a; Li and Huang, 2006b), which delivered siRNA to tumor cells in the B16F10 
xenograft model (Li et al., 2008b; Li et al., 2008c). In previous work, Huang and colleagues 
demonstrated enhanced tumor cell-specific uptake of this NP formulation by surface-
modification with anisamide, a ligand of the sigma receptor, which is up-regulated in many 
cancers (John et al., 1995; Vilner et al., 1995) and is expressed in B16F10 cells (Banerjee et 
al., 2004; Li et al., 2008b; Li et al., 2008c; Li and Huang, 2006a). 
Our findings show that delivery of Bcl-x SSO by the LPD NP resulted in 
modification of Bcl-x mRNA splicing in lung metastases and reduction of tumor load. This 
marks the first demonstration of SSO-induced splicing modification in tumor cells in vivo 
and provides support for Bcl-x splice-switching as a potential anti-tumor strategy.  
Materials and Methods 
Materials 
2′-O-methoxyethyl (MOE)-phosphorothioate SSOs (Figure 2.1) were synthesized by 
ISIS Pharmaceuticals (Carlsbad, CA). The Bcl-x SSO was targeted to the 5′ splice site of 
exon II in Bcl-x pre-mRNA (5′-TGGTTCTTACCCAGCCGCCG-3′, ISIS 105751) (Zhang et 
al., 2007). An oligonucleotide targeted to aberrantly spliced human β-globin intron (5′-
GCTATTACCTTAACCCAG-3′, ISIS 18204) (Sazani et al., 2002) was used as negative 
control. For nanoparticle preparation cholesterol, protamine sulfate, calf thymus DNA and 
cloning water were purchased from Sigma-Aldrich (St. Louis, MO). DOTAP stock solution 
(20 mg/ml) was purchased from Avanti Polar Lipids (Alabaster, AL).  
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Cell culture and transfection  
B16F10 mouse melanoma cells expressing sigma receptors were used as model cells 
in this study (Pham et al., 2007). B16F10 cells stably expressing the firefly luciferase gene 
were provided by Dr. Pilar Blancafort  (University of North Carolina, Department of 
Pharmacology, NC) (Li et al., 2008b). The cells were maintained in high-glucose Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum and a 5% 
penicillin/streptomycin solution (GIBCO, Grand Island, NY) at 37ºC and 5% CO2. Cells 
were seeded in 96, 24 or 6-well plates at 7.5 × 103, 7.0 × 105 and 5.0 × 105 cells/well, 
respectively, approximately 24 hours prior to transfection. Cells were transfected with 
LipofectAmine 2000 (Invitrogen) in Opti-MEM  (Invitrogen) per the manufacturer’s 
recommendation.  
RNA Isolation and analysis 
Total RNA from cells or tissue was isolated using TRI Reagent (Molecular Research 
Center, Cincinnati, OH, USA) according to the manufacturer’s protocol using 800 µl for ~5 
mg tissue samples. Next, 200 ng of total RNA was subjected to RT-PCR (5′-
CATGGCAGCAGTGAAGCAAG-3′, Bcl-x forward primer; 5′-
GCATTGTTCCCGTAGAGATCC-3′, Bcl-x reverse primer; 5′-
GTGCAGCGCAACCACGAGAC-3′, Mcl-1 forward primer; 5′-
GCAGCACATTTCTGATGCCG-3′, Mcl-1 reverse primer) with rTth polymerase (Applied 
Biosystems, Foster City, CA). Cycles of PCR proceeded at 95ºC for 3 min, followed by 22 
cycles of 95ºC for 30 s, 56ºC for 30 s, and 72ºC for 1 min. The PCR contained Cy5-
conjugated dCTP (GE Healthcare) for visualization. The PCR products were separated on a 
10% nondenaturing polyacrylamide gel (Invitrogen) and bands were visualized on a Typhoon 
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9400 Imager (GE Healthcare). Images were quantified using ImageQuant analysis software 
(Version 5.2, Molecular Dynamics). The percentage of Bcl-xS in each lane was determined 
by dividing the intensity of the 162 bp band (Bcl-xS) by the total intensities of the 351 (Bcl-
xL) and 162 bp (Bcl-xS) bands. The identity of the 162 bp band was confirmed by sequencing 
by the UNC-CH Genome Analysis Facility. 
Cell viability assay 
Cell viability in response to SSO treatment was assessed, with slight modifications, 
by a previously described clonogenic assay (Mercatante et al., 2002). Briefly, 24 h after 
oligonucleotide transfection in 6-well plates, 250 cells were re-plated in 10-cm plates. After 
10 days under normal culture conditions surviving colonies were stained with 2% methylene 
blue (Sigma) in 50% ethanol for 10 min. Colonies larger than 50 cells were counted. 
Western Blot Analysis  
Cells (5.0 × 105 cells/well in a 6-well plate) were washed twice with ice-cold PBS and 
lysed in RIPA buffer (radioimmune precipitation assay buffer; 50 mM Tris-HCl, 150 mM 
NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, and 1% sodium deoxycholate) and a 
cocktail of protease inhibitors (Sigma). Total protein was quantified with the Quick Start 
Bradford Protein Assay Kit (Bio-Rad Laboratories, Inc., Hercules, CA). Total protein (20 µg) 
was separated by electrophoresis on a 4-12% pre-cast Bis-Tris gel (Invitrogen) and 
electrotransferred to a polyvinylidene difluoride (PVDF) membrane. Membranes were 
stained with Ponceau’s stain to confirm equal loading and transfer. Membranes were blocked 
for 1 hour in BLOTTO (5% w/v nonfat dry milk in TBS, 0.1% Tween) or StartingBlock 
Buffer (Pierce) and incubated overnight at 4ºC with primary antibodies: polyclonal Bcl-x 
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antibody (1:2000; BD Transduction Labs), polyclonal PARP antibody (1:2000; Cell 
Signaling 9452) and mouse anti-β-actin monoclonal antibody (1:10,000; Sigma).  
Membranes were then incubated for 1 hour with horseradish peroxidase-conjugated anti-
mouse (1:100,000; Sigma) or goat anti-rabbit (1:10,000; Abcam) secondary antibodies. Blots 
were developed with ECL Plus reagents (GE Healthcare) and exposed to film (GE 
Healthcare). Bcl-xL, Bcl-xS, β-actin, cleaved PARP and full-length PARP migrated at 30, 22, 
42, 89 and 116 kDa respectively. β-actin was used to confirm equal protein loading.  
For the detection of Bcl-xS levels, B16F10 cells were plated at 2.0 × 10
5 cells/plate in 
60 mm2 plates. Cells were transfected with 4 ug Bcl-xS plasmid DNA (pcDNA3.1-Bcl-xS 
graciously provided by Dr. Reuven Stein, Tel Aviv University, Tel Aviv, Israel) using 
LipoFectamine 2000 according to the manufacturer’s protocol. Approximately 24 hours later, 
the transfected cells were rinsed twice with PBS and suspended using Trypsin-EDTA. 
B16F10 cells tranfected with pcDNA3.1-Bcl-xS were then diluted in un-transfected B16F10 
cells at various ratios: 1:2, 1:5, 1:10, 1:25, 1:50 and 1:100. Cells were then subjected to RNA 
and protein isolation and analysis as described above. 
Preparation of SSO-containing nanoparticles  
Liposome-protamine-DNA (LPD) nanoparticles (NP) were prepared as previously 
described (Li et al., 2008b; Li et al., 2008c). Briefly, naked NP were obtained by quickly 
mixing 150 µl suspension A (16.6 mM liposomes (DOTAP/cholesterol molar ratio = 1: 1, 
and 400 µg/ml protamine in 5% dextrose) with 150 µl solution B (320 µg/ml oligonucleotide 
and 320 µg/ml calf thymus DNA in 5% dextrose) followed by incubation at room 
temperature for 10 min. The naked NP suspension (300 µl) was further incubated with 
75.6 µl micellar solution of DSPE-PEG2000-anisamide (10 mg/ml) (synthesized in the Huang 
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lab as reported earlier (Banerjee et al., 2004)) at 50°C for 10 min and then allowed to stand at 
room temperature for 10 min. The resulting formulation was used within 20 min for the 
following experiments. These methods resulted in encapsulation of >90% oligoncuelotide or 
siRNA in previous studies (Chono et al., 2008; Li and Huang, 2006b; Li and Huang, 2009).  
Animal Studies  
Female C57BL/6 mice of ages 6–8 weeks (16–18 g) were purchased from Charles 
River Laboratories (Wilmington, MA). All experiments performed on the animals were in 
accordance with and approved by the Institutional Animal Care and Use Committee at the 
University of North Carolina. The mouse model was established by i.v. injection of 2 × 105 
luciferase-expressing B16F10 cells on day 0. In the preliminary study, tumor-bearing animals 
were seven days after tumor inoculation injected i.v. with NP formulated with Bcl-x SSO at 
2.4 mg/kg either (a) everyday for a total of nine injections, or (b) every other day for a total 
of five injections. The negative control group received no treatment. Animals were 
euthanized one day following the final injection (day 16 after tumor inoculation). RNA was 
isolated from tumor nodules and analyzed by RT-PCR. Following this preliminary 
experiment, a larger-scale study was designed and implemented in which animals were i.v. 
injected with vehicle only (PBS), NP only (2.4 mg/kg), control or Bcl-x SSO NP (2.4 
mg/kg), or free control or  Bcl-x SSO (2.4  or 10 mg/kg) on days 3–6 after tumor inoculation. 
On day 7, some animals were euthanized for analysis of RNA splicing. For animals treated 
with free SSO, only RNA was analyzed. For animals treated with NP, blood was collected 
for analysis of toxicity marker. On day 17 the remaining animals were euthanized for the 
analysis of tumor load. Tumor load was determined by measuring luciferase activity within 
tumor-bearing lungs, as described previously (Li et al., 2008b; Li et al., 2008c).  
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Toxicity Assays  
Twenty-four hours after the final injection, blood samples were collected and serum was 
isolated. Analyses of serum aspartate aminotransferase and alanine aminotransferase were 
performed at the Animal Clinical Laboratory Core Facility (University of North Carolina) 
using a Vitro 250 Chemical Analyzer (Ortho-Clinical Diagnostics, Rochester, NY).  Serum 
interleuikin-12 was measured with the enzyme-linked immunosorbant assay (ELISA) 
according to the manufacturer’s protocol (BD Biosciences, San Diego, CA). 
Statistical Analysis. Luciferase data were analyzed by one-way analysis of variance 
(ANOVA) and Tukey’s post-test using Prism statistical software (GraphPad, version 4.03). 
Results 
Modification of Bcl-x pre-mRNA in melanoma cells 
 Transfection of B16F10 cells with MOE-PS Bcl-x SSO targeted to the downstream 5′ 
splice site of Bcl-x exon 2 (Figure 2.1) induced a dose-dependant shift in splicing of Bcl-x 
pre-mRNA from anti-apoptotic Bcl-xL to pro-apoptotic Bcl-xS, while a control SSO had no 
effect on splicing (Figure 2.2 A, B). Consistent with these results, probing of total protein 
from treated cells with anti-Bcl-x antibody showed SSO-dependent reduction in the level 
Bcl-xL protein (Figure 2.2 C). We were unable to detect the expected Bcl-xS protein because 
the endogenous level of murine Bcl-xS expression was below the threshold required by 
available antibodies (Figure 2.3). Importantly, SSO treatment resulted also in a dose-
dependant decrease in cell viability, as evidenced by a clonogenic cell death assay. (Figure 
2.4 A). This was accompanied by cleavage of poly (ADP-ribose) polymerase (PARP), 
indicating that the observed cell death was due to apoptosis (Figure 2.4 B). These effects 
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were absent in untreated and mock-transfected cells, and cells transfected with a control 
SSO. In addition, the Bcl-x SSO had no effect on the pre-mRNA splicing of Mcl-1, a closely 
related gene that shares sequence homology at the 5′ splice site, supporting sequence 
specificity of the Bcl-x SSO (Figure 2.5).  
Activity of Bcl-x SSO in vivo 
 To facilitate SSO delivery to cancer cells in tumor-bearing mice, an LPD NP 
developed by the Huang laboratory was used (Li et al., 2008b; Li et al., 2008c). The SSO and 
a carrier DNA (calf thymus DNA) were complexed by protamine into a compact core which 
was then coated with cationic lipids to form the NP (Figure 2.6). The surface of the NP was 
further modified with an anisamide ligand-conjugated polyethylene glycol (PEG)-lipid for 
targeting the sigma receptor-expressing B16F10 cells. This NP formulation could efficiently, 
specifically and with low toxicity deliver siRNA to tumor cells in the B16F10 tumor model, 
as shown previously (Li et al., 2008b; Li et al., 2008c).  
 B16F10 murine melanoma cells localize in the lungs shortly after injection into the 
tail vein of C57BL/6 mice. In the absence of treatment, the mice die approximately 22 days 
following inoculation (Li et al., 2008c).  This rapid course of disease dictated the treatment 
protocol (see Materials and Methods). RT-PCR analysis of total RNA from the tumor-
bearing lungs of animals euthanized on day 7 showed induction of Bcl-xS mRNA expression 
in animals treated with the Bcl-x SSO NP formulation. This effect was dose-dependant, as 
increasing the number of injections resulted in a greater degree of Bcl-x splice-switching 
from Bcl-xL to Bcl-xS mRNA in the tumor nodules (Figure 2.7). In contrast, Bcl-xS mRNA 
levels in animals treated with control SSO NP formulation or free SSO were no different than 
in animals treated with PBS only (Figure 2.7, 2.8 A). Modification of Bcl-x splicing in the 
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liver was barely detectable in Bcl-x SSO-treated animals and undetectable in animals treated 
with control SSO NP or PBS only (Figure 2.8A). As a measure of tumor load, luciferase 
activity was assayed in lysates from tumor-bearing lungs of animals euthanized on day 17. A 
dramatic reduction in luciferase activity was seen in animals treated with Bcl-x SSO NP 
compared to animals treated with NP only, control SSO NP, or PBS only (Figure 2.8 B, C). 
Statistical analysis (ANOVA, Tukey’s post-test) revealed that the reduction in luciferase 
activity in animals treated with Bcl-x SSO NP was significant compared to animals treated 
with PBS only (P < 0.001), NP only (P < 0.05) and control SSO NP (P < 0.05) (Figure 2.8 
B).  
Toxicity studies 
 To determine the potential toxicities of NP and SSO treatment, serum levels of 
toxicity markers were analyzed in mice euthanized on day 7 following tumor inoculation. 
Tissues with a leaky endothelial wall, such as the liver, allow significant uptake of 
nanoparticles (Li and Huang, 2008). Accordingly, we analyzed serum aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) levels as markers of liver 
toxicity. No significant elevation in serum AST or ALT among treatment groups was 
observed (Figure 2.9 A, B). To test the possibility that components of the NP formulation 
might trigger an inflammatory response, serum levels of the pro-inflammatory cytokine IL-
12 were also analyzed. Elevated IL-12 levels relative to the PBS control were observed in NP 
treatment groups (Empty NP, P<0.01; Control SSO P<0.001) (Figure 2.9 C). 
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Discussion 
Alternative splicing has emerged as an important target for molecular therapies 
(Bauman et al., 2009). Clinical trials using SSOs to treat DMD have yielded promising 
preliminary results (Kinali et al., 2009; van Deutekom et al., 2007), while numerous recent 
reports have confirmed the in vivo efficacy of SSOs in treating animal models of disease 
(Bauman et al., 2009). SSOs have been applied against cancer targets in vitro (Mercatante et 
al., 2001; Mercatante et al., 2002; Wan et al., 2009), however in vivo validation of their 
efficacy has been hindered by the poor delivery of antisense therapeutics to tumor cells in 
vivo (Bennett, 2008; Juliano et al., 2009b). Here we show that an SSO in LPD NP 
formulation was effective in delivery to tumor cells in the B16F10 model system (Li et al., 
2008b; Li et al., 2008c; Li and Huang, 2006a).    
Our data indicate that SSO-induced redirection of Bcl-x pre-mRNA splicing from 
Bcl-xL to -xS induced apoptosis and subsequent cell death in a dose-dependant manner in 
B16F10 melanoma cells in culture (Figure 2.2, 2.3). In vivo, redirection of Bcl-x pre-mRNA 
splicing was associated with a significant reduction of tumor burden in rapidly growing and 
highly tumorigenic B16F10 lung metastases (Figure 5A-C). This finding is consistent with 
our in vitro data, as well as previous work in prostate and breast cancer cells (Mercatante et 
al., 2001; Mercatante et al., 2002). Interestingly, in this model both in cell culture and in vivo 
xenografts, modification of Bcl-x pre-mRNA splicing alone induced cell death, whereas in 
non-small cell lung carcinoma (A549) cells adjuvant chemotherapy was needed (Taylor et 
al., 1999). Bcl-xL expression may therefore be critical for survival of B16F10 cells, 
consistent with reports that increased Bcl-xL expression is associated with melanoma 
progression and metastasis (Leiter et al., 2000; Zhuang et al., 2007). Thus, other 
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pharmacological agents that target Bcl-xL may warrant further investigation in metastatic 
melanoma. 
 Our cell culture data are consistent with the predicted SSO mechanism of action. 
Namely, that Bcl-x SSO-induced modulation of Bcl-x pre-mRNA splicing, reduced the level 
of Bcl-xL, and increased the level of Bcl-xS splice variants, causing apoptosis of cancer cells. 
This is evident at the RNA level, and is further supported by the dramatic reduction of Bcl-xL 
protein and by induction of PARP cleavage (Figure 2C, 3C). Although SSO induced Bcl-xS 
mRNA we were unable to confirm concomitant production of Bcl-xS protein by 
immunoblotting procedures. This was in spite of screening several commercially available 
antibodies and including attempts to concentrate the protein by immunoprecipitation prior to 
Western analysis. This is likely because the maximum level of endogenous Bcl-xS protein 
that could be induced by the SSO was below that which could be detected by available 
antibodies (Supplementary Figure 1).  
 In vivo, RT-PCR analysis of total RNA from tumor-bearing lungs demonstrated that 
Bcl-x splicing was shifted approximately 10% from Bcl-xL to the -xS splice variant. Yet this 
treatment led to marked reduction of tumor load in treated animals. Two interpretations of 
these results are possible. One, that in vivo even a minor reduction of Bcl-xL levels and 
concomitant increase in Bcl-xS, leads to death of cancer cells or at least inhibits their 
proliferation. However, it is also possible that the cells which took up the SSO more 
efficiently were more effectively killed by apoptosis and thus eliminated from the tissue 
subjected to subsequent analysis.  If this is the case, RT-PCR underestimates the actual level 
of SSO-induced splice-switching.  
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BH3 mimetics comprise a novel class of cancer drugs that competitively antagonize 
the Bcl-2 anti-apoptotic proteins (Chonghaile and Letai, 2008). For example, the small 
molecule ABT-737 binds Bcl-2, Bcl-xL and Bcl-w proteins with nanomolar affinity. It 
induced apoptosis in lymphoma and small-cell lung carcinoma cells in culture, and caused 
tumor regression and improved survival in preclinical studies (Oltersdorf et al., 2005). By 
modifying the splicing pattern of Bcl-x, the SSO can be thought of as prompting the tumor 
cell to produce an endogenous BH3 mimetic, Bcl-xS, capable of antagonizing Bcl-2 and Bcl-
xL and promoting apoptosis.  
Nanoparticles are known to accumulate non-specifically in the liver due to the 
fenestrated vasculature (Li and Huang, 2008). We did not observe significant Bcl-x splice-
switching in the liver (Figure 5A), and ALT and AST serum levels were not significantly 
elevated in treatment groups relative to the PBS control (Figure 6). This suggests that liver 
uptake of the NP was limited and did not translate into significant biological activity or 
toxicity. We did detect a modest elevation of serum IL-12 levels in NP treatment groups 
relative to the PBS control (Figure 6). A previous report with the LPD NP showed more 
pronounced induction of inflammatory toxicity at doses ≥1.2 mg/kg (Li et al., 2008a; Li et 
al., 2008c). However, that study analyzed local toxicity from lung lysate, whereas we 
analyzed serum from systemic circulation. It is unclear whether this small but statistically 
significant increase is biologically relevant. Elevated IL-12 could be due to unmethylated 
CpG motifs present in the calf thymus DNA component of the NP. While we cannot exclude 
the possibility that the observed IL-12 increase contributed to the anti-tumor effect of the 
Bcl-x SSO, this seems unlikely because IL-12 induction was observed in all NP treatment 
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groups, whereas reduction of tumor load was only evident in animals treated with the Bcl-x 
SSO.  
The inclusion of calf thymus DNA in the NP complicates the use of this formulation 
from a pharmaceutics and regulatory perspective. Recently, Chono et al. replaced calf 
thymus DNA with a high molecular weight anionic polysaccharide, hyaluronic acid, resulting 
in a NP containing cationic liposome, protamine and hyaluronic acid (LPH) (Chono et al., 
2008). The LPH formulation delivered siRNA in vivo with potency similar to that of the LPD 
formulation; however, induction of both IL-6 and IL-12 cytokines by LPH was significantly 
lower than that of the corresponding LPD containing the calf thymus DNA. The LPH NP 
formulation could be employed for delivery of SSOs to tumors in future studies. 
Despite the caveats described above, it is encouraging that this NP formulation, 
developed primarily for in vivo delivery of siRNA, was found to deliver functionally active 
SSO to tumor cells. As mentioned in the Introduction, siRNAs do not support extensive 
chemical modifications because of specifications imposed by the RISC-loading process. As a 
result, efforts to improve siRNA delivery in vivo have been a major source of progress in the 
development of NP formulations. Our results suggest that advances in the NP-aided delivery 
of siRNA may be leveraged for the delivery of non-siRNA oligonucleotide therapeutics, 
including SSOs and RNase H-active ASOs. However, it should be noted that the LPD NP 
and similar iterations could not be sued to deliver uncharged oligonucleotides, such as PNA 
and PMO, because charge is necessary for association with and condensing by polyanionic 
protamine. 
Tumor xenograft models, such as the one used in this study, are widely used for the 
preclinical evaluation of putative anti-cancer drugs. These models have drawn criticism 
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because they do not always predict which drugs will succeed in the clinic (Sharpless and 
Depinho, 2006). To address this criticism, SSOs targeting Bcl-x and other cancer targets 
could be tested in alternative cancer models such as orthotopic tumor or genetically 
engineered mouse models (Kerbel, 2003). 
Our results extend previous findings on the LPD NP formulation, which delivered 
siRNA to the cytoplasm, the site of dicer activity, to oligonucleotides that function in the 
nucleus, the site of splicing modulation. Thus, through delivery of SSOs, liposome-based NP 
formulations may be used not only to down-regulate, but also to up-regulate endogenous 
gene expression, as is evidenced by the induction of Bcl-xS mRNA we observed. In addition, 
our findings are consistent with Bcl-x pre-mRNA splice-switching as a possible anti-tumor 
strategy in melanoma as well as other malignancies expressing Bcl-xL. 
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Figure 2.1 Direction of Bcl-x alternative splicing by SSO.  
(A) Use of the downstream or upstream alternative 5′ splice site within exon II of Bcl-x pre-
mRNA yields anti-apoptotic Bcl-xL or pro-apoptotic Bcl-xS, respectively. SSO targeted to the 
downstream splice site redirects the splicing machinery to the upstream alternative splice 
site, resulting in a simultaneous decrease in production of Bcl-xL and increase in production 
of Bcl-xS. (B) Chemical structure of 2′-O-methoxyethyl (MOE) phosphorothioate (PS) 
oligonucleotide. The MOE ribose modification confers RNAse-H non-competence and 
increased affinity for target mRNA, while the phosphorothioate inter-nucleotide linkage 
improves serum stability and bioavailability. 
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Figure 2.2 SSO induced Bcl-x splice-switching in B16F10 murine melanoma cells.  
(A) RT-PCR analysis of Bcl-x mRNA from cells transfected with control and Bcl-x SSO 24 
hours post-transfection. The Bcl-x SSO induces dose-dependant switching of Bcl-x mRNA 
splicing from anti-apoptotic Bcl-xL to pro-apoptotic Bcl-xS. Error bars indicate mean ± SD 
(n=3). (B) Sequence analysis of the RT-PCR product corresponding to Bcl-xS showing exons 
2 and 3 joined at the upstream alternative splice site. (C) Immunoblot analysis of cells treated 
with 100 nM Bcl-x SSO 48 hours post-transfection. The SSO induces a reduction in the Bcl-
xL protein isoform. Detection of β-actin confirms equal loading. 
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Figure 2.3 Bcl-xS detection by RT-PCR and Western Blot. 
B16F10 cells transfected with pcDNA3.1-Bcl-xS were diluted with untransfected cells at 
various ratios (undiluted, 1:2, 1:5, 1:10, 1:25, 1:50, 1:100). RNA and protein were isolated 
and analyzed by RT-PCR and Western Blot, respectively. Bcl-xS mRNA was readily detected 
even at the 1:100 dilution, though it was not detected in untransfected cells. Bcl-xS protein 
could be detected up to the 1:5 dilution, but was not seen in more dilute samples. The level of 
Bcl-xS mRNA corresponding to the 1:5 dilution is greater than can achieved endogenously 
through alternative splicing.  
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Figure 2.4 Bcl-x SSO induces cell death in B16F10 murine melanoma cells.  
(A) Effect of Bcl-x and control SSO on cell viability as determined by a clonogenic assay. 
Top panel shows images of representative plates at 80 nM concentration. Bottom left panel 
expresses viability of SSO-treated cells relative to untreated cells. Error bars indicate mean ± 
SD (n=3-4). Bottom right panel shows viability of cells treated with 1 µM staurosporine 
(STS) relative to DMSO-treated cells.  (B) Western blot of protein from cells treated with 
control and Bcl-x SSOs for 24 hours. The presence of PARP cleavage in Bcl-x SSO-treated 
cells confirms that the observed decrease in cell viability is due to apoptosis. Detection of β-
actin confirms equal loading. 
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Figure 2.5 Bcl-x SSO does not affect Mcl-1 alternative pre-mRNA splicing.  
(A) The Bcl-x and Mcl-1 share a high degree of sequence conservation at the 5′ splice site of 
exon 2. As a result the Bcl-x SSO matches 13 out of 20 bases in Mcl-1 pre-mRNA (including 
one G-U pair). (B) RNA from Bcl-x SSO-transfected B16F10 cells was subjected to RT-PCR 
using primers flanking exon 2 of mouse Mcl-1. Mcl-1 pre-mRNA can be alternatively spliced 
to produce a transcript that lacks exon 2. However, the Bcl-x SSO fails to redirect Mcl-1 
splicing, despite matching 13 out of 20 bases in Mcl-1. SSO concentrations used were 4, 11, 
33, 100 and 300nM. 
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Figure 2.6 Schematic depiction of the preparation of SSO encapsulated LPD NP.  
The SSO was encapsulated into a condensed core with a high molecular weight polyanion 
(calf thymus DNA) and protamine, which was then coated with cationic liposomes. PEG 
lipids were inserted into the resultant bilayer to shield the positive charge and prevent 
aggregation in circulation. Anisamide, a commonly used targeting ligand that binds the sigma 
receptor, was conjugated to the distal end of the PEG lipids.
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Figure 2.7 Systemically-delivered free Bcl-x SSO has no effect on Bcl-x pre-mRNA 
splicing in tumor xenografts. 
Tumor-bearing animals were injected with vehicle only (PBS) or with free SSO (control SSO 
or Bcl-x SSO) in PBS at 2.4 or 10 mg/kg on days 3-6 following tumor inoculation. On day 7 
animals were euthanized and RNA from tumor-bearing lungs was isolated and analyzed by 
RT-PCR. 
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Figure 2.8 Bcl-x splice-switching depends on the dose of Bcl-x SSO NP formulation.  
(A) Bcl-x SSO NP was systemically delivered (tail-vein injection) every day (9 injections, 
group A) or every over day (5 injections, group B) to mice bearing B16F10 tumors. (B) RT-
PCR analysis of Bcl-x pre-mRNA isolated from lung tumor nodules from mice injected with 
2.4 mg/kg NP formulated with Bcl-x SSO every day (9 injections, group A) or every over 
day (5 injections, group B) revealed robust Bcl-x splice-switching. 
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Figure 2.9 Effects of LPD-NP-delivered SSO in B16F10 tumor-bearing lungs.  
(A) RT-PCR analysis of Bcl-x mRNA splicing in the tumor-bearing lungs (upper panel) and 
liver (lower panel) of mice treated with vehicle only (PBS), empty NP, control SSO-
formulated NP and Bcl-x SSO-formulated NP. (B) Luciferase activity in the tumor-loaded 
lungs on day 17 after injections on days 3-6. Asterisks denote statistical significance 
thresholds (*P < 0.05, **P < 0.001, determined by ANOVA and Tukey’s post-test). 
Untreated n = 26, NP only n = 8, Control SSO NP n = 13, Bcl-x SSO NP n = 9. (C) 
Representative images of lungs excised from tumor-bearing mice on day 17 following 4 
injections of 2.4 mg/kg NP formulations on days 3-6.  
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Figure 2.10 Serum enzyme and cytokine analysis.  
ALT (A), AST (B) and IL-12 (C) serum levels of untreated tumor-free and tumor-bearing 
C57BL/6 mice 24 hours after the last of 4 consecutive daily treatments. Treatments consisted 
of i.v. injections of vehicle only (PBS), NP formulated with control SSO, or NP formulated 
with SSO targeted to Bcl-x.  
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Chapter 3 – Modification of Mcl-1 alternative splicing with splice-switching 
oligonucleotides induces apoptosis and enhances chemosensitivity 
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Abstract 
Mcl-1 transcripts are alternatively spliced to produce proteins with opposing 
functions. Inclusion of all three exons produces Mcl-1L, an anti-apoptotic protein that is 
highly expressed in many malignancies and confers resistance to chemotherapeutic drugs. 
Skipping of exon 2 leads to expression of Mcl-1S, a potent pro-apoptotic protein expressed at 
low levels in most cells. We used RNAse H non-competent splice-switching oligonucleotides 
targeted to the 5′ and 3′ splice sites in Mcl-1 pre-mRNA, thereby blocking recognition by the 
spliceosome and modifying the pattern of alternative splicing. Modification of Mcl-1 splicing 
from Mcl-1L to -1S induced PARP cleavage and cell death in HeLa cells, indicative of 
apoptosis. Mcl-1 splice-switching also sensitized cells staurosporine. These findings validate 
Mcl-1 as a target for splice-switching strategies to induce apoptosis and sensitize cancer cells 
to chemotherapy.   
Introduction 
The ability of tumor cells to evade apoptosis is a hallmark of cancer (Hanahan and 
Weinberg, 2000), prompting the search for drugs that can restore normal apoptotic signaling 
in tumor cells (Fesik, 2005). Apoptosis is regulated by death receptor-mediated (extrinsic) 
and mitochondria-mediated (intrinsic) pathways, which converge on the activation of 
caspases, which in turn initiate a proteolytic cascade leading to the cell death phenotype. 
Apoptotic signaling through the intrinsic pathway requires permeabilization of the outer 
mitochondrial membrane and the consequent efflux of pro-apoptotic factors, such as 
cytochrome C.  
Mitochondrial membrane integrity is regulated by interactions among members of the 
Bcl-2 family. Apoptotic stimuli prompt Bax and Bak to oligomerize at the outer 
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mitochondrial membrane, resulting in membrane permeability and effluc of pro-apoptotic 
factors such as cytochrome C.  Anti-apoptotic Bcl-2 homologs, such as Bcl-2, Bcl-xL and 
Mcl-1L, bind and sequester Bax and Bak, preventing the cell from committing to apoptosis. 
BH3-only proteins, such as Noxa, Puma, Bad and Bim, are activated by diverse apoptotic 
signals, such as DNA damage and growth factor deprivation, prompting their translocation to 
the mitochondria, where they competitively bind the anti-apoptotic homologs, liberating Bax 
and Bak to oligomerize and trigger apoptosis. (Adams and Cory, 2007; Uren et al., 2007; 
Willis et al., 2007). The balance of BH3-only and anti-apoptotic Bcl-2 proteins thus 
determines whether the cell will commit to apoptosis. Upregulation of anti-apoptotic Bcl-2 
homologues enables them to overcome antagonism by BH3-only proteins, causing resistance 
to apoptosis. Consequently, overexpression of a anti-apoptotic family member can be 
oncogenic and, since many chemotherapeutics induce apoptosis through activation of BH3-
only proteins, the upregulation of Bcl-2 anti-apoptotic proteins by tumor cells promotes 
chemoresistance (Amundson et al., 2000; Huang and Strasser, 2000).  
The Mcl-1 gene encodes three exons and its pre-mRNA transcript is alternatively 
spliced to produce splice variants with opposing function (Figure 3.1). Inclusion of all three 
exons produces the anti-apoptotic Bcl-2 homolog Mcl-1L encoding three basic helical 
domains (BH1-3) and a C-terminal transmembrane domain responsible for its localization at 
the mitochondrial. BH domains 1–3  form a hydrophobic groove on the protein surface, 
which is the site of interaction with Bak and BH3-only proteins, including Noxa, Puma, Bim 
and Bad (Chen et al., 2005; Willis et al., 2005). Mcl-1L is overexpressed in a number of 
malignancies, including cervical cancer (Chung et al., 2002; Wei et al., 2001a), chronic 
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myeloid leukemia (Aichberger et al., 2005), and multiple myeloma (Zhang et al., 2002). High 
Mcl-1L expression confers resistance to the BH3 mimetic ABT-737 (Tahir et al., 2007).  
Skipping of exon 2 in Mcl-1 pre-mRNA causes a frame-shift in the translation of 
exon three, leading to the production of Mcl-1S, a truncated protein encoding a BH3 domain 
and a novel C-terminus (Bae et al., 2000; Bingle et al., 2000). Mcl-1S was found to potently 
induce apoptosis in a manner that inhibited by caspase blockade. The apoptotic activity was 
also inhibited fully by Mcl-1L and partially by Bcl-xL and Bcl-w (Bae et al., 2000). Mcl-1S 
was also found to bind Mcl-1L. Taken together, these findings sugges that Mcl-1S act as a 
BH3-only protein that antagonizes Mcl-1L (Bae et al., 2000; Bingle et al., 2000).  
Over 90% of multi-exon gene transcripts undergo alternative splicing (Wang et al., 
2008) and up to 50% of disease-causing mutations affect splicing (Lopez-Bigas et al., 2005). 
Accordingly, alternative pre-mRNA splicing has emerged as important therapeutic target 
(Cooper et al., 2009). Our laboratory and others have developed splice-switching 
oligonucleotides (SSOs), chemically modified antisense compounds that hybridize to pre-
mRNA sequences involved in splicing, thereby blocking access to the transcript by splicing 
factors and influencing splice site usage (Dominski and Kole, 1993; Sierakowska et al., 
1996). SSOs have been used to repair aberrant pre-mRNA splicing, modulate alternative 
splicing patterns, and induce expression of novel splice variants (Bauman et al., 2009). 
Here SSOs have been employed to switch the alternative splicing pattern of Mcl-1 
from predominant expression of Mcl-1L to Mcl-1S, thereby converting an anti-apoptotic 
molecule into a pro-apoptotic one. Mcl-1 splice-swtiching induced apoptosis and enhanced 
chemosensitivity in cells in culture. 
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Methods and Materials 
Materials 
2′-O-methyl phosphorothioate oligonucleotides targeted to the 5′ and 3′ splice sites of 
exon II of Mcl-1 pre-mRNA (Figure 3.1A) were synthesized by the UNC Program in 
Macromolecular Therapeutics Oligonucleotide Synthesis Core Facility. The sequences are 
available upon request. One SSO sequence for each splice site was chosen for further study 
and SSOs 2′-O-methoxyethyl phosphorothioate SSOs were synthesized by Integrated DNA 
Technologies, Inc. (IDT):  5′-GTTTCCGAAGCATGCCTGAG-3′ (5' splice site) and 5′-
TCCTTAAGGCAAACTTACCC-3′ (3' splice site). An oligonucleotide targeted to aberrantly 
spliced human β-globin intron (5′-GCTATTACCTTAACCCAG-3′, ISIS18204) provided by 
ISIS Pharmaceuticals (Carlsbad, CA) (Sazani et al., 2002), was used as negative control. 
Plasmid DNA expressing FLAG-tagged Mcl-1S (pcDNA3-Mcl-1S) was generously provided 
by J. Bae (CHA University, South Korea).The chemotherapeutic pan-kinase inhibitor 
staurosporine (Sts) was purchased, already in-solution at 1 mM in DMSO, from Sigma-
Aldrich (S6942; St. Louis, MO).  
Cell culture and transfection 
  HeLa cervical cancer cells and Sk-Mel147 melanoma cells were maintained in high-
glucose Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum 
and a 5% penicillin/streptomycin solution (GIBCO, Grand Island, NY) at 37ºC and 5% CO2. 
HeLa cells were seeded in 96- or 12-well plates at 1.0 × 103 and 1.0 × 105 cells/well, 
respectively, approximately 24 hours prior to transfection. Sk-Mel147 cells were seeded in 
12-well plates at 1.5 × 105 cells/well. Cells were transfected with LipofectAmine 2000 
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(Invitrogen) in Opti-MEM  (Invitrogen) per the manufacturer’s recommendation. SSO and 
plasmid DNA transfections were performed in 1:3 serial dilutions. For Mcl-1S plasmid 
transfection, half of the cells were used for isolation of total RNA and half were used for 
isolation of total protein.   
RNA Isolation and analysis 
Total RNA from cells was isolated using TRI Reagent (Molecular Research Center, 
Cincinnati, OH, USA) according to the manufacturer’s protocol using 800 µl per well for a 
24-well plate. Next, 200 ng of total RNA was subjected to RT-PCR (5′-
CCTGATGCCACCTTCTAGGTCC-3′, forward primer; 5′-
CTCTCGGTACCTTCGGGAGC-3′, reverse primer) with rTth polymerase (Applied 
Biosystems, Foster City, CA). Cycles of PCR proceeded at 95ºC for 3 min, followed by 22 
cycles of 95ºC for 30 s, 56ºC for 30 s, and 72ºC for 1 min. The PCR contained Cy5-
conjugated dCTP (GE Healthcare) for visualization. The PCR products were separated on a 
10% nondenaturing polyacrylamide gel (Invitrogen) and bands were visualized on a Typhoon 
9400 Imager (GE Healthcare). Images were quantified using ImageQuant analysis software 
(Version 5.2, Molecular Dynamics). The percentage of Mcl-1S in each lane was determined 
by dividing the intensity of the 194 bp band (Mcl-1S) by the total intensities of the 442 bp 
(Mcl-1L) and 194 bp (Mcl-1S) bands. The identity of the 194 bp band was confirmed by 
sequencing by the UNC-CH Genome Analysis Facility.  
Western Blot Analysis  
Cells (1.0 × 105 cells/well in a 12-well plate) were washed twice with ice-cold PBS 
and lysed in RIPA buffer (radioimmune precipitation assay buffer; 50 mM Tris-HCl, 150 
mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, and 1% sodium deoxycholate) 
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supplemented with protease inhibitor cocktail (Sigma). Total protein was quantified by BCA 
using the Protein Assay Reagent (Pierce). Total protein (10 µg) was separated by 
electrophoresis on a pre-cast 4-12% Bis-Tris gel (Invitrogen) and electrotransferred onto a 
polyvinylidene difluoride (PVDF) membrane. Membranes were stained with Ponceau’s stain 
to confirm equal loading and transfer. Membranes were blocked for 30 min in Blotto, 
consisting of Tris-buffered saline supplemented with 0.1% Tween 20 (TBS-T) and nonfat dry 
milk (5% w/v). Membranes were subsequently incubated overnight at 4ºC with the following 
primary antibodies in Blotto: polyclonal Mcl-1 antibody (1:3000; Santa Cruz Biotechnology, 
S-19), polyclonal PARP antibody (1:3000; Cell Signaling 9452) and mouse anti-β-actin 
monoclonal antibody (1:10,000; Sigma).  Membranes were then incubated for 1 hour with 
horseradish peroxidase-conjugated anti-mouse (1:100,000; Sigma) or goat anti-rabbit 
(Abcam, 1:10,000) secondary antibodies. Blots were developed with ECL Plus reagents (GE 
Healthcare) and exposed to film (GE Healthcare). Mcl-1L, Mcl-1S, β-actin, cleaved PARP 
and full-length PARP migrated at 40, 32, 45, 89 and 116 kDa respectively. β-actin was used 
to confirm equal protein loading. 
Cell death and chemosensitization assays 
 Cell death in response to SSO, plasmid DNA or staurosporine (Sts) treatment was 
measured by MTS assay (Promega). Cell viability was calculated relative to mock-
transfected cells. For the chemosensitization study, six hours after transfection with SSO, the 
cell culture medium was replaced with medium containing various doses of Sts. Cells were 
incubated for 48 hours and then cell viability was calculated relative to untreated cells and 
normalized to the lowest Sts dose for each treatment group. Cell death and dose-response 
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curve data were analyzed by one-way analysis of variance (ANOVA) and Dunnett's post-test 
using Prism statistical software (GraphPad, version 4.03). 
Results 
Modification of Mcl-1 pre-mRNA splicing by SSO 
The pro-apoptotic protein Mcl-1S is translated from an mRNA transcript in which 
exon 2 is excluded through alternative splicing. However, this isoform is expressed at low 
levels in most cells. We predicted that steric block of either the 5′ or 3′ splice site of exon 2 
with SSOs would prompt exon exclusion, thereby increasing expression of Mcl-1S (Figure 3 
A). To test this hypothesis, we first screened 2′-O-methyl (2OMe) phosphorothioate (PS) 
SSOs designed to hybridize to sequences surrounding the 5′ and 3′ splice sites of Mcl-1 exon 
2. We used 2OMe SSOs in the initial screen because they can be inexpensively synthesized 
and do not support RNase H. HeLa cells transfected with 25 nM SSOs targeted to either 
splice site (SSOs 09-16) induced a concomitant down-regulation of Mcl-1L and an up-
regulation of Mcl-1S mRNA (Figure 3.1 B). Splice-switching efficacies did not differ 
dramatically among SSOs targeted to the same splice site; however, at the 25 nM SSO 
concentration tested, the 5′ SSOs (SSO11-16) appeared to be slightly more potent inducers of 
splice-switching than the 3′ SSOs (SSO05-10). 
For further study we decided to use 2′-O-methoxyethyl (MOE) SSOs because 2OMe 
oligonucleotides exhibit non-specific toxicity which would complicate the interpretation of 
results from apoptosis studies. Accordingly, MOE PS SSOs were synthesized for further 
study using the sequences corresponding to SSO9 and SSO16. HeLa cells were transfected 
with various concentrations of SSO21 and SSO22, which hybridize to the 5′ or 3′ splice sites 
of exon 2, respectively. RT-PCR analysis showed a dose-dependent redirection of Mcl-1 pre-
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mRNA splicing (EC50 ≈ 20 nM for SSO22, EC50 ≈ 10 nM for SSO21) (Figure 3.2 A). 
Sequence analysis confirmed joining of exons one and three in the RT-PCR product (Figure 
3.2 B). As a negative control, cells were mock-transfected or transfected with an SSO 
targeted to intron two of aberrantly-spliced β-globin (SSO654), which had no effect on Mcl-1 
pre-mRNA splicing (Figure 3.2 A). Mcl-1S was rapidly induced by SSO22 and redirection of 
splicing peaked at approximately 12 hours following transfection and persisted out to 72 
hours. Mcl-1 splice switching was also demonstrated in Skmel-147 cells (Figure 3.2 D). The 
induction of Mcl-1S mRNA was inhibited by the transcription inhibitor actinomycin D 
(10µg/ml), but not the translation inhibitor cycloheximide (1 and 10µg/ml) or the pan-caspase 
inhibitor Z-VAD-fmk (50 µM) (Figure 3.3).  
Western blot analysis of cells transfected with SSO22 showed a dose-dependent 
down-regulation of Mcl-1L protein and up-regulation of Mcl-1S protein, confirming that Mcl-
1S protein generated by SSO was translated into protein (Figure 3.4 A, B). Levels of Mcl-1L 
and -1S protein were unchanged in the negative control groups.  
Apoptosis and cell death induced by Mcl-1 Splice-switching 
Next, we tested the hypothesis that the observed redirection in Mcl-1 pre-mRNA 
splicing would lead to increased apoptosis. Cells were transfected with various 
concentrations of SSO22 and 24 or 48 hours later total protein lysate was isolated and 
subjected to SDS-PAGE. Western Blot analysis showed a dose-dependent increase in the 
cleavage of poly (ADP-ribose) polymerase (PARP), a target of caspase cleavage 
representative of apoptosis induction (Figure 3.4 A, B). There was no PARP cleavage 
observed in cells treated with SSO654 control. Actin was used as a loading control. 
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To test whether modification of Mcl-1 pre-mRNA splicing from Mcl-1L to Mcl-1S is 
sufficient to induce cell death, cells were transfected with various concentrations of SSO22 
and SSO654 control. Forty-eight hours later, cell viability was measured by MTS assay. 
Relative to mock-transfected cells, SSO22-treated cells showed a dose-dependant reduction 
in cell viability absent in SSO654-treated cells (P<0.01 for 50–150 nM) (Figure 3.5 A). 
Plasmid expression of Mcl-1S was also sufficient to trigger cell death, consistent with 
previous reports (P<0.05 for 0.17µg, P<0.05 for 0.5µg) (Bae et al., 2000; Bingle et al., 2000). 
The levels of Mcl-1S expression in SSO- and plasmid-transfected cells were compared by 
normalizing to β-actin expression in each sample (Figure 3.5 B). The level of Mcl-1S 
expression induced by 50–150 nM SSO22 transfection was similar to that which was induced 
by 0.06–0.16 ug Mcl-1S plasmid transfection.   
Chemosensitization induced by SSO 
Next we tested the hypothesis that redirection of Mcl-1 pre-mRNA splicing could 
render the affected cells more sensitive to chemotherapeutic agents. Six hours after 
transfection with SSO22 and SSO654 control, cells were treated with various concentrations 
of the pan-kinase inhibitor staurosporine and incubated for 48 hours. Cells pre-treated with 
SSO22 exhibited a significant shift in the dose-response to staurosporine compared to mock-
transfected cells (P < 0.05) (Figure 3.6). 
Discussion 
The anti-apoptotic protein Mcl-1L is emerging as an important therapeutic target for 
the treatment of cancer. Amplification of the Mcl-1 and high levels of Mcl-1L have been 
detected in a broad range of cancer types, suggesting a general role for Mcl-1L in the survival 
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of cancer cells. In this study we sought to exploit the high tumor cell expression of Mcl-1 
through the redirection of alternative splicing to generate a potent pro-apoptotic protein, Mcl-
1S, thereby reducing the tumor cell's ability to evade apoptosis. To this end, we employed 
SSOs comprised of RNase H non-competent 2OMe or MOE modified bases to bind and 
block either the 5′ or 3′ splice site of exon 2 of Mcl-1 pre-mRNA to force exon 2 skipping. 
The degree of Mcl-1 splice-switching induced by a given SSO is presumably due to 
the relative ability of each SSO to block the interaction of the splicing machinery with 
sequence elements. As a result, SSOs can exhibit dramatically different efficacies despite 
targeting to nearby or overlapping sequences depending on the presence of splice sites or 
regulators sequence elements within the target sequence (Graziewicz et al., 2008; Hua et al., 
2007). In our initial screen, all 2OMe SSOs targeted to the same splice site exhibited 
comparable splice-switching efficiencies, suggesting that they utilized the same mechanism 
of action, namely steric blocking of either the 5′ or 3′ splice site. Blockade of the 5' splice site 
resulted slightly more potent antisense activity than blockade of the 3' splice site for both 
2OMe and MOE SSOs. It is not unusual for the 5′ and 3′ splice sites to exhibit different 
sensitivities to SSOs. For example, 5′ SSOs were more effective than 3′ SSOs at skipping of 
exon 2 in MyD88 pre-mRNA (Vickers et al., 2006). In a detailed analysis of exon 23 
skipping in dystrophin pre-mRNA the 5′ SSOs were found to be effective while the 3′ splice 
site was insensitive to SSOs (Mann et al., 2002). 
When investigating novel agents for potential apoptotic activity, it is critical to 
minimize non-specific toxicity that would compromise the interpretation of experimental 
results. MOE oligonucleotides have been reported to exhibit lower non-specific toxicity 
relative to 2OMe in cell culture (Bennett and Swayze, 2010). Hence, once Mcl-1 splice-
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switching was validated by the 2OMe SSO screen, further investigation of Mcl-1 splicing-
switching was carried out using MOE SSOs. As predicted by the initial screen, transfection 
of MOE SSO22 and SSO21 resulted in the modification of Mcl-1 pre-mRNA splicing in 
Hela cells. (Figure 3.1 A, B). SSO22 was chosen for subsequent experiments to avoid 
potential off-target confounds due to the high degree of sequence homology at the 5′ splice 
site of exon 2 among Bcl-2 family members (See chapter 2, Figure 2.5). 
To assess if de novo protein synthesis was required for Mcl-1 splice-switching, we 
tested the effect of SSO22 in the presence of the protein synthesis inhibitor cycloheximide. 
Cycloheximide did not inhibit production of Mcl-1S, suggesting that SSO-induced splice-
switching did not require de novo protein synthesis (Figure 3.3). It is possible that the SSO 
led only to down-regulation of Mcl-1L, which could trigger apoptosis and promote the 
caspase-dependent degradation of components of the splicing machinery, thereby causing 
general disruption of splicing. Indeed, spliceosomal components and RNA-binding proteins 
can be targets for caspases (Back et al., 2002; Waterhouse et al., 1996). However, addition of 
the pan-caspase inhibitor Z-VAD-fmk did not abrogate production of Mcl-1S mRNA induced 
by SSO22 (Figure 3.3). To test whether mRNA transcription was required for SSO-induced 
splice-switching, we tested the effect of SSO22 in the presence of the transcription inhibitor 
actinomycin D. Actinomyin D completely inhibited the expression of Mcl-1S induced by 
SSO22 (Figure 3.3). SSO22 also induced splice-switching was also observed in cell lines 
other than HeLa (Figure 3.2D and observations by J.A.B.), indicating that this effect was not 
an experimental artifact confined to HeLa cells. Taken together, these results suggest that 
SSO22 required transcription but not translation or capsase activation to induce expression of 
Mcl-1S mRNA, which is consistent with the predicted splice-switching mechanism of action.  
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The modification of Mcl-1 splicing by SSO22 was rapid, achieving maximal splice-
switching at approximately 12 hours post-transfection (Figure 3.2 C). The rapid induction of 
Mcl-1S was consistent with the high turnover previously report for Mcl-1 mRNA (Yang et 
al., 1996). The observed mRNA splice-switching by SSO was accompanied by a dose-
dependent decrease in Mcl-1L protein and increases in Mcl-1S protein and PARP cleavage 
(Figure 3.4 A, B).  Twenty-fours post-transfection, SSO concentrations of  ≥50 nM resulted 
in >75% Mcl-1S mRNA and approximately 50% Mcl-1S protein relative to Mcl-1L mRNA 
and protein levels, respectively (Figures 3.2 A, 3.4 A). Still, our data likely underestimate the 
true levels of SSO-induced Mcl-1S mRNA and protein because a significant portion of the 
affected cells underwent apoptosis and thus were removed from the sample from which RNA 
and protein could be isolated and analyzed (Figure 3.5 A). At the protein level, the total level 
of Mcl-1 protein (i.e. Mcl-1L + Mcl-1S) in SSO22-treated cells appeared to less than the total 
level of Mcl-1 protein detected in negative control cells. This could have been caused by 
more efficient apoptosis of cells expressing higher levels of Mcl-1. In this case, only low 
Mcl-1 expressing cells—with less Mcl-1 pre-mRNA to convert into pro-apoptotic Mcl-1S 
and perhaps relying on compensatory expression of anti-apoptotic Bcl-xL and/or Bcl-2—
would remain for protein isolation, resulting in the lower total Mcl-1 protein observed by 
Western Blot. An alternative explanation is that the antibody used Mcl-1 detection exhibited 
different affinities for the two splice variants. 
SSO22-induced modification of Mcl-1 splicing and PARP cleavage was accompanied 
by dose-dependent reduction in cell viability, indicating that SSO22 induced apoptotic cell 
death. We wanted to explore the extent to which the observed cell death induced by SSO22 
by was due to up-regulation of Mcl-1S. It has been shown that Mcl-1S induces cell death 
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when overexpressed with plasmid DNA (Bae et al., 2000). The level of Mcl-1S expression 
that can be induced by SSO is dependent on endogenous expression. By titrating the amount 
of DNA used for transfection, we show that Mcl-1S can induce cell death when expressed at 
levels comparable to those that can be induced by SSO (Figure 3.5 A, B). However, SSO22 
was evidently more effective at inducing cell death than Mcl-1S. This suggests that cell death 
induced by SSO22 is a function of both Mcl-1L down-regulation and Mcl-1S up-regulation. 
Because of the important role of Mcl-1L in enabling tumor cells to evade apoptosis, 
we asked whether Mcl-1 splice-switching could render cells more sensitive to chemotherapy. 
Pre-treatment of cells with SSO22 caused a shift in their dose-response to staurosporine, 
providing evidence of chemosensitization by Mcl-1 splice-switching. This finding is 
important because at the highest concentration tested about half of the cells remained viable 
when treated with SSO22 alone. Simultaneous treatment with chemotherapeutic agents, such 
as staurosporine, may be necessary to maximize the apoptosis-promoting potential of Mcl-1 
splice-switching. 
During the course of this investigation, another group reported the modification of 
Mcl-1 splicing in basal carcinoma cells using PMO SSOs (Shieh et al., 2009). Interestingly, 
targeting both the 5′ and 3′ splice sites simultaneously failed to a shift in Mcl-1 splicing 
>50% at the highest PMO concentration tested. They detected a modest induction of 
apoptosis (25% annexin V-positive cells vs. 10% in controls) and cell death was not reported.  
DNA damaging agents, such as UV irradiation, cisplatin and etoposide, were found to 
induce poly-ubiquitination and subsequent proteasomal degradation of Mcl-1L via the E3 
ubiquitin ligase Mule. Mule encodes a BH3 domain that is required for its poly-ubiquitation 
of Mcl-1L. Like the pro-apoptotic BH3-only proteins, Mule is thought to bind via its BH3 
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domain to the hydrophobic pocket in Mcl-1L formed by its BH1–3 domains. Because Mcl-1S 
lacks the BH1 and BH2 domains, it cannot form this binding site and is presumably not poly-
ubiquitinated by Mule in response to DNA damage. In the presence of DNA damaging 
agents, Mcl-1S induced by SSO might persist while Mcl-1L is targeted for degradation. This 
possibility should be further studied. 
Interestingly, elimination of Mcl-1L by RNAi or by Noxa-mediated proteasomal 
degradation was required but not sufficient for apoptosis in HeLa cells (Cuconati et al., 2003; 
Nijhawan et al., 2003). The fact that Mcl-1 splice-switching induced apoptosis in this study 
could be the result of Mcl-1S up-regulation by the SSO, especially if Mcl-1S has pro-
apoptotic functions outside of Mcl-1L antagonism. For example, Mcl-1S could bind and 
antagonize other Bcl-2 family members, such as Bfl-1/A1. Based on sequence homology, 
Bfl-1/A1 and Mcl-1L are more closely related to each other than to Bcl-2, Bcl-xL or Bcl-w 
(Petros et al., 2004). Mcl-1S failed to bind the latter proteins in a yeast two-hybrid assay; 
however, binding between Mcl-1S and Bfl-1/A1 has not been investigated. Alternatively, 
apoptosis induced by Mcl-1 splice-switching could be result of differences in the particular 
HeLa sublcones used in the different studies. 
Our results confirm that blockade of either the 5′ or 3′ splice site of exon 2 in Mcl-1 
pre-mRNA with SSOs results in a modification of splicing from Mcl-1L to -1S. Mcl-1 splice-
switching resulted in dose-dependent increases in Mcl-1S protein expression and apoptotic 
cell death. We also show, for the first time, sensitization to chemotherapeutics induced by 
Mcl-1 splice-switching.  
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Figure 3.1. 2′-O-methyl  SSOs targeted to the 3′ and 5′ splice sites of Mcl-1 exon 2 
modify the pattern of alternative splicing.  
(A) Inclusion of all three exons from Mcl-1 pre-mRNA results in expression of anti-apoptotic 
Mcl-1L while skipping of exon 2 results in expression of pro-apoptotic Mcl-1S. (B) RNase H 
non-competent 2′-O-methyl SSOs targeted to the 3′ or 5′ splice site of exon 2 induce 
expression of Mcl-1S mRNA. 
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Figure 3.2 2′-O-methoxyethyl (MOE) SSOs targeted to the 5′ or 3′ splice site of exon 2 
modify the pattern of Mcl-1 alternative splicing. 
(A) Modification of Mcl-1 alternative splicing using MOE SSOs targeted to the 5′ (SSO21) 
or 3′ splice site (SSO22) of exon 2 in Mcl-1 pre-mRNA. Splice-switching is dose-dependent 
and absent in cells treated with a control SSO (SSO654). (B) Sequences analysis of PCR 
bands corresponding to Mcl-1S induced by SSO22 (3′ splice site) and SSO21 (5′ splice site) 
confirm skipping of exon 2. (C) Time-course of Mcl-1 splice-switching by SSO22. (D) SSO-
induced Mcl-1 splice-switching in Skmel-147 melanoma cells indicates that SSO activity is 
not an artifact confined HeLa cells.  
104 
 
 
 
 
Figure 3.3 SSO induction of Mcl-1S mRNA requires transcription but not translation or 
caspase activation. 
HeLa cells were pre-treated with the transcriptional inhibitor actinomycin D (ActD, 10 
µg/µl), the translational inhibitor cycloheximide (CHX, 1 and 1 µg/µl), and the pan-caspase 
inhibitor Z-VAD-fmk (50 µM), and then transfected with either negative control (SSO654) or 
Mcl-1 3′ SSO (SSO22). Only transcriptional inhibition blocks expression of Mcl-1S, 
consistent with the SSO acting by modification of splicing, as expected.    
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Figure 3.4 SSO induces Mcl-1S protein expression and apoptosis in a dose-dependent 
manner. 
Western blot analysis of cells transfected with SSO22 or SSO654 control for 24 (A) or 48 (B) 
hours. SSO22 induced a dose-dependent increase in Mcl-1S protein and a concomitant 
decrease in Mcl-1L expression. SSO22 also induced a dose-dependent increase in cleavage of 
PARP, a target of caspases. SSO654 control had no effect on the expression of Mcl-1 protein 
or PARP cleavage. 
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Figure 3.5 SSO-induced Mcl-1 splice-switching results in cell death. 
(A) Cell transfected with SSO22 or Mcl-1S plasmid undergo dose-dependent cell death as 
determine by MTS assay. * P<0.05, **P<0.01. (B) RT-PCR analysis of mRNA from cells 
transfected with SSO or Mcl-1S plasmid. Expression of Mcl-1S mRNA was normalized to 
that of β-actin and the ratios of Mcl-1S to β-actin as a measure of Mcl-1S are listed. 
Expression of Mcl-1S plasmid at levels comparable to that which can be induced by SSO22 
resulted in cell death.  
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Figure 3.6 SSO-induced Mcl-1 splice-switching sensitizes cells to staurosporine.  
Cell were transfected with SSO22 or SSO654 control and subsequently treated with 
increasing concentrations of the pan-kinase inhibitor staursporine (STS). The cells were 
incubated for 48 hours and then cell death was measured by MTS assay. Pre-treatment with 
SSO22 resulted in shift in the dose-response to staurosporine. 
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Summary of Results 
Early studies by Mercatante et al. and Taylor et al. established that RNase H non-
competent splice-switching oligonucleotides (SSOs) targeted to the downstream (Bcl-xL) 5′ 
splice site of exon 2 in Bcl-x pre-mRNA could modify the pattern of Bcl-x splicing in vitro. 
They further showed that Bcl-x splice-switching induced apoptotic cell death and 
chemosensitization in breast, prostate and lung cancer cells. I have recapitulated these results 
in a murine melanoma cell line. These in vitro results demonstrate the promise of Bcl-x 
splice-switching as a therapeutic strategy; however, the anti-cancer potential of Bcl-x splice-
switching remained to be validated in a setting that more faithfully reproduces the 
microenvironment of a tumor in vivo. Using a lipid nanoparticle (LPD NP) to aid delivery, I 
showed that SSOs could induce Bcl-x splice-switching in melanoma xenografts; this result 
constituted the first demonstration of pre-mRNA splicing modification in tumor cells in vivo. 
Importantly, the observed Bcl-x splice-switching was associated with a reduction in tumor 
burden absent in the animals in negative control treatment groups.  
Delivery is a chief concern for the application of oligonucleotide drugs. The first and 
only approved oligonucleotide drug, Vitravene, and the RNA aptamer drug Macugene, are 
administered by intravitreal injection, essentially circumventing many of the biological 
barriers typically encountered by systemically administered drugs. In order to realize the full 
therapeutic utility of SSOs, these barriers will have to be overcome. Lipid nanoparticles, such 
as the LPD NP used herein, have been effective at in vivo delivery of siRNA and SSO in 
mouse xenograft models (Bauman et al., 2010; Li et al., 2008a; Li et al., 2008b; Li et al., 
2008c; Li and Huang, 2006a). These formulations are comprised of multiple components 
(e.g., liposomes, carrier molecules, targeting ligands) making their approval for use in 
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humans complicated from a regulatory and pharmaceutics perspective; immunotoxicity is 
also a concern.  Further study and continued optimization of the LPD NP should improve 
upon these limitations. For example, Chono et al. showed that substituting calf thymus DNA 
with hyaluronic acid reduced immunostimulation caused by high doses of the NP (Chono et 
al., 2008). Although clinical utility of the LPD NP has not yet been established, it proved to 
be useful tool for the in vivo evaluation of Bcl-x SSOs. Future iterations of the LPD NP 
should be considered for the study and validation other splice-switching targets in cancer.  
Several studies using animal models show that uptake, potency and cell targeting of 
PMO SSOs can be improved by the addition of arginine-rich cell-penetrating peptides (CPP) 
(Ivanova et al., 2008; Jearawiriyapaisarn et al., 2008; Jearawiriyapaisarn et al., 2010; Wu et 
al., 2009; Wu et al., 2008; Yin et al., 2008b; Yokota, 2008). Hence, CPP conjugates warrant 
further study for tumor targeting and delivery of SSOs. 
In addition to Bcl-x, there are numerous alternatively-spliced transcripts implicated in 
cancer that constitute potential targets for splice-switching strategies (Table 4.1). Among 
these candidates, Mcl-1 undergoes alternative splicing to produce anti-apoptotic Mcl-1L, 
which has been linked to the pathogenesis of a variety of cancers, and pro-apoptotic Mcl-1S, 
which is expressed at very low levels. In this dissertation, I showed that SSOs targeted to the 
5′ or 3′ splice site of exon 2 in Mcl-1 pre-mRNA modify the pattern of splicing from Mcl-1-L 
to -1S. Mcl-1 splice-switching induced apoptosis and cell death, and sensitized cells to 
staurosporine. These findings provide evidence that Mcl-1 splice-switching is a potential 
anti-cancer strategy.  
As with Bcl-x splice-switching, the efficacy of Mcl-1 SSOs should be evaluated for 
anti-cancer effects in in vivo systems.  Multiple myeloma would make a good candidate for 
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future Mcl-1 splice-switching studies for several reasons. First, Mcl-1L expression was 
established as a critical survival factor for multiple myeloma (Zhang et al., 2002). Second, 
patient samples can be readily obtained and treated with SSOs ex vivo; this might represent 
the heterogeneous disease state more accurately than immortalized cell lines. Finally, in vivo 
delivery to circulating myeloma cells might present fewer challenges than delivery to solid 
tumors. Numerous studies have demonstrated that knockdown of Mcl-1L sensitizes resistant 
cells lines to the pan-Bcl-2 inhibitor ABT-737 (Chen et al., 2007; van Delft et al., 2006; 
Wesarg et al., 2007). Accordingly, the ability of Mcl-1 SSOs to synergize with ABT-737 and 
other cancer therapeutics warrants future study.  
The finding that Bcl-x splice-switching resulted in anti-cancer activity in vivo adds to 
the mounting evidence supporting the therapeutic utility of ASOs in general and SSOs in 
particular. The approval of Vitravene in 1998, indicated for the treatment of cytomegalovirus 
retinitis in immunocompromised patients, demonstrates the capacity of antisense drugs to 
meet regulatory requirements for safety and efficacy. Promising RNase H-active ASOs in 
late-stage clinical trials include Mipomersan, which targets Apolipoprotein-B100 for 
treatment of hypercholesterolemia, and OGX-011, which targets clusterin for treatment of 
cancer. In addition, SSOs that restore dystrophin expression in DMD patients are progressing 
in the clinic (Table 4.2) (Kinali et al., 2009; Sazani et al., 2010; van Deutekom et al., 2007). 
As illustrated in Table 4.2, there are now numerous oligonucleotide therapeutics 
currently under clinical investigation for treatment of cancer. All of these drug candidates 
utilize the RNase H or siRNA mechanism of action, and therefore down-regulate gene 
expression. Despite a rich and growing pool of cancer targets suitable for splice-switching 
strategies (Table 4.1) there are presently no ongoing clinical trials using SSOs for the 
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treatment of cancer. This observation, coupled with the recent progress of SSOs for non-
cancer indications, indicate that SSOs aimed at cancer therapy occupy a largely unexploited 
niche at the intersection of splice-switching and anti-cancer drugs. This is likely the result of 
poor delivery of previously tested oligonucleotides to tumors, a problem which I have begun 
to address with the research presented in this dissertation. As delivery vehicles continue to 
improve, splice-switching as a strategy for cancer therapy should move closer to becoming a 
reality. Importantly, Bcl-x and Mcl-1 have recently been validated as key genes in numerous 
cancers (Beroukhim et al., 2010), providing additional impetus for continuation of the work 
initiated here.  
 
113 
 
 
Role in cancer Gene Splice variants Cellular effect 
Apoptosis 
Bcl-x Bcl-xL 
Anti-apoptotic, up-regulated in cancers, promotes 
chemoresistance 
    Bcl-xS Pro-apoptotic, antagonizes Bcl-xL and Bcl-2 
  
Mcl-1 Mcl-1L 
Anti-apoptotic, up-regulated in cancers, promotes 
chemoresistance 
    Mcl-1S Pro-apoptotic, antagonizes Mcl-1L 
  Caspase-2 Caspase-2L Pro-apoptotic 
    Caspase-2S Anti-apoptotic, protects against chemotherapeutics 
  Caspase-9 Caspase-9 Pro-apoptotic 
    Caspase-9B Anti-apoptotic, inhibits apoptosome formation 
  Survivin Survivin Anti-apoptotic, up-regulated in cancers 
    Survivin-2B Pro-apoptotic, antagonizes survivin 
Cell proliferation Fas Fas Mediates apoptotic signaling 
  
  FasExo8Del 
Inhibits Fas-mediated apoptosis, up-regulated in 
certain cancers 
  HER2 HER2 Promotes proliferation and survival of cancer cells 
  
  Herstatin 
Pro-apoptotic, soluble dominant-negative inhibitor 
or HER2 
  
  ∆15HER2 
Pro-apoptotic, soluble dominant-negative inhibitor 
or HER2 
  
Rac1 Rac1 
Regulates cell proliferation and cytoskeletal 
reorganization 
  
  Rac1b 
Increased rate of GDP/GTP exchange leads to 
constitutive activation, transforms cells in 
culture, expressed exclusively in tumors tissue 
Angiogenesis 
VEGF VEGFA 
Promotes angiogenesis through activations of 
VEGF receptors 1 and 2, up-regulated in many 
cancers 
  
  VEGF165b 
Inhibits angiogenesis through competitive inhibition 
of VEGF receptor 2 
Transcription factors p53 p53 Tumor suppressor, transcription factor 
    p47 Antagonizes p53 tumor suppressor 
  KLF6 KLF6 Tumor suppressor, transcription factor 
    KLF6-SV1 Antagonizes KLF6, up-regulated in certain cancers 
 
Table 4.1 Alternatively-spliced gene transcripts important in cancer. 
Listed are examples of genes involved in the proliferation, survival and chemoresistance of 
cancer cells that express splice variants with different functions [Comprehensively reviewed 
in (David and Manley, 2010; Mercatante and Kole, 2002; Schwerk and Schulze-Osthoff, 
2005)]. This non-comprehensive list suggests a richness of potential targets for splice-
switching strategies for cancer therapy.  
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Drug Indication Target Mechanism Chemsitry Route Status 
Fomiversen Cytomegalovirus IE2 gene RNase H PS ODN Intravitreal Approved 
Genasense Cancer Bcl-2 RNase H PS DNA Systemic Phase 3 
Mipomersen Cardiovascular Apolipoprotein B RNase H MOE gapmer Systemic Phase 3 
Trabederen Cancer 
Transforming growth 
factor-β 
RNase H PS DNA Intratumoral Phase 3 
LOR-2040 Cancer Ribonucleotide reductase RNase H PS DNA Systemic Phase 3 
Archexin Cancer AKT-1 RNase H PS DNA Systemic Phase 3 
Custirsen Cancer Clusterin RNase H MOE gapmer Systemic Phase 3 
TPI ASM8 Asthma 
CCR3 and IL-5 (two 
oligomers) 
RNase H PS DNA Inhaled Phase 2 
Alicaforsen Colitis 
Intracellular adhesion 
molecule-1 
RNase H PS DNA Enema Phase 2 
AEG35156 Cancer X-IAP RNase H 2OMe gapmer Systemic Phase 2 
TV.ATL1102 
Multiple 
sclerosis 
CD49D RNase H 2OMe gapmer Systemic Phase 2 
LY2181308 Cancer Survivin RNase H MOE gapmer Systemic Phase 2 
ISIS111317 Diabetes, type 2 
Protein tyrosine 
phosphatase-B 
RNase H MOE gapmer Systemic Phase 2 
Monarsen 
Myasthenia 
gravis 
Acetylcholine esterase RNase H MOE gapmer Oral Phase 2 
PRO-051 DMD Dystrophin 
Splice-
switching 
2OMe Systemic Phase 2 
AVI-4658 DMD Dystrophin 
Splice-
switching 
PMO Systemic Phase 2 
ALNSRV-01 
Respiratory 
syncytial virus 
Nucleocapsid N gene siRNA 
dsRNA 
(unmodified) 
Inhaled Phase 2 
PF-4523655 
Age-related 
macular 
degeneracy 
 RTP801 siRNA 
dsRNA 
(unmodified) 
Intravitreal Phase 2 
AIR 645 Asthma eIF-4E RNase H MOE gapmer Inhaled Phase 1 
ISIS-CRP Diabetes 
Sodium-dependent 
glucose transporter 2 
RNase H MOE gapmer Intravitreal Phase 1 
iCO-007 
Macular 
degeneration 
 C-raf kinase RNase H MOE gapmer Systemic Phase 1 
LY2275796 Cancer eIF-4E RNase H MOE gapmer Systemic Phase 1 
OGX-427 Cancer Heat shock protein 27 RNase H MOE gapmer Systemic Phase 1 
SPC2996 Cancer Bcl-2 RNase H LNA gapmer Systemic 
Phase 
1/2 
EZN2968 Cancer 
Hypoxia inducing factor 1-
α 
RNase H LNA gapmer Systemic Phase 1 
EZN3042 Cancer Survivin RNase H LNA gapmer Systemic Phase 1 
PRO044 DMD Dystrophin 
Splice-
switching 
2OMe Systemic Phase 1 
QPI-1102 
Acute kidney 
injury 
p53 siRNA dsRNA Systemic Phase 1 
ALN-VSP Cancer 
Vascular endothelial 
growth factor 
siRNA 
Modified 
dsRNA in 
liposome 
formulation 
Systemic Phase 1 
CALAA-01 Cancer Ribonucleotide reductase siRNA 
dsRNA in 
nanoparticulate 
formulation 
Systemic Phase 1 
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Table 4.2 Oligonucleotide drugs currently in clinical trials or marketed. 
Listed are examples of oligonucleotide drugs in clinical trials. There are currently three SSO 
drugs in clinical trials, all for treatment of Duchenne Muscular Dystrophy. All of the drug 
candidates indicated for cancer utilize the RNase H or siRNA mechanism of action, and thus 
are all down-regulate target gene expression. Many of the late-phase candidates utilize PS 
DNA chemistry, which is vulnerable to enzymatic cleavage and is rapidly cleared. For this 
reason, early-phase candidates utilizing PMO, MOE and LNA chemistries are more likely to 
gain approval and commercial success. Source: www.ClinicalTrials.gov.
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